[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 465
1. Kiguchi T, Yoshino Y, Yuan B, Yoshizawa S, Kitahara T, Akahane D, Gotoh M, Kaise T, Toyoda H, Ohyashiki K: Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leuk Res; 2010 Mar;34(3):403-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.
  • We assessed concentrations of arsenic trioxide (As(2)O(3)) and its metabolites in the plasma and cerebrospinal fluid in acute promyelocytic leukemia patients who achieved complete remission with intravenous As(2)O(3).
  • Results suggest that a combinatory treatment of As(2)O(3) with other chemotherapeutics could be effective for APL patients with CNS involvement.
  • [MeSH-major] Antineoplastic Agents / cerebrospinal fluid. Arsenicals / cerebrospinal fluid. Leukemia, Promyelocytic, Acute / cerebrospinal fluid. Oxides / cerebrospinal fluid
  • [MeSH-minor] Adult. Chromatography, High Pressure Liquid. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19733394.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


2. Morimatsu Y, Matsubara S, Hirose N, Ohkuchi A, Izumi A, Ozaki K, Ozawa K, Suzuki M: Acute promyelocytic leukemia: an unusual cause showing prolonged disseminated intravascular coagulation after placental abruption. Arch Gynecol Obstet; 2008 Mar;277(3):267-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia: an unusual cause showing prolonged disseminated intravascular coagulation after placental abruption.
  • We closely observed her, and at the 58th day postpartum, blast cells appeared in the peripheral blood and she was diagnosed with acute promyelocytic leukemia (APL).
  • CONCLUSION: APL should be added to the list of differential diagnosis when DIC persists even after prompt delivery and appropriate anti-DIC treatment after placental abruption.
  • [MeSH-major] Abruptio Placentae / etiology. Disseminated Intravascular Coagulation / etiology. Leukemia, Promyelocytic, Acute / diagnosis. Pregnancy Complications, Neoplastic / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Cesarean Section. Female. Humans. Neutropenia / etiology. Pregnancy

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713776.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Ades L, Chevret S, De Botton S, Thomas X, Dombret H, Beve B, Sanz M, Guerci A, Miguel JS, Dela Serna J, Garo C, Stoppa AM, Reman O, Stamatoulas A, Fey M, Cahn JY, Sotto JJ, Bourhis JH, Parry A, Chomienne C, Degos L, Fenaux P, European APL Group: Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia; 2005 Feb;19(2):230-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience.
  • We analyzed the outcome of patients aged more than 60 included in a multicenter trial in newly diagnosed acute promyelocytic leukemia (APL93 trial), which tested the role of early addition of chemotherapy to all trans retinoic acid (ATRA) and of maintenance with ATRA and/or low-dose chemotherapy.
  • The 4-year incidence of relapse was 15.6% in adults older than 60 and 23.2% in younger adults although most elderly patients received less intensive consolidation chemotherapy.
  • APL in elderly patients appears as sensitive to ATRA-Chemotherapy based regimen as in younger adults.
  • Less favorable outcome is mainly due to an increase of early deaths and to toxicity of consolidation treatment, strongly suggesting a beneficial role for less intensive consolidation chemotherapy and possibly introduction of arsenic derivates in the treatment of APL in the elderly.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Europe. Female. Humans. Male. Middle Aged. Recurrence. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15565164.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


Advertisement
4. Yamakura M, Araki K, Kimura S, Odawara J, Aoki T, Takeuchi M, Matsue K: Use of urine cytology in the diagnosis of genitourinary relapse of acute promyelocytic leukemia after allogenic stem cell transplant. Int J Hematol; 2008 Oct;88(3):251-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of urine cytology in the diagnosis of genitourinary relapse of acute promyelocytic leukemia after allogenic stem cell transplant.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / pathology. Leukemia, Promyelocytic, Acute / urine. Stem Cell Transplantation. Urine / cytology. Urogenital Neoplasms / pathology. Urogenital Neoplasms / urine
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18807121.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Nollet S, Berger E, Deconinck E, Baldauf E, Rumbach L: [Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone]. Rev Neurol (Paris); 2006 Feb;162(2):195-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone].
  • Since 1998, eight cases of acute leukemia (AL) have been described.
  • In spite of a very low total dose (58.32 mg), she developed promyelocytic AL.
  • DISCUSSION: All the reported cases of AL occurring after Mx respond to the criteria of leukemia induced by anti-topoisomerases II.
  • Epidemiological data and those from animal experiments suggest that Mx has direct role in the occurrence of leukemia.
  • CONCLUSION: It must be remembered that even if the risk of Mx-induced leukemia is low, blood cell counts must be closely monitored for at least five years after the last injection of this treatment.
  • [MeSH-major] Analgesics / adverse effects. Leukemia / etiology. Mitoxantrone / adverse effects. Multiple Sclerosis / complications. Multiple Sclerosis / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Blood Cell Count. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rev Neurol (Paris). 2006 Feb;162(2):157-9 [16518255.001]
  • (PMID = 16518259.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Analgesics; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


6. Naithani R, Kumar R, Mahapatra M: Fournier's gangrene and scrotal ulcerations during all-trans-retinoic acid therapy for acute promyelocytic leukemia. Pediatr Blood Cancer; 2008 Aug;51(2):303-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fournier's gangrene and scrotal ulcerations during all-trans-retinoic acid therapy for acute promyelocytic leukemia.
  • Scrotal ulcers are a rare manifestation in patients with acute promyelocytic leukemia.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Fournier Gangrene / chemically induced. Leukemia, Promyelocytic, Acute / drug therapy. Scrotum / pathology. Tretinoin / adverse effects. Ulcer / chemically induced
  • [MeSH-minor] Adolescent. Adult. Humans. Male

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18421710.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


7. Gokcan MK, Batikhan H, Calguner M, Tataragasi AI: Unilateral hearing loss as a presenting manifestation of granulocytic sarcoma (chloroma). Otol Neurotol; 2006 Jan;27(1):106-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To present a case of acute granulocytic sarcoma of the cerebellopontine angle whose presenting symptom was sudden onset unilateral sensorineural hearing loss.
  • METHODS: A 34-year-old female patient with acute myeloid leukemia on remission admitted because of sudden hearing loss in her right ear for 10 days.
  • The patient presented in this report is the first reported case with a granulocytic sarcoma of the cerebellopontine angle who presented with acute sensorineural hearing loss.
  • Despite the rarity of such a case, we would like to emphasize that leukemia must be kept in mind as an etiologic factor in sensorineural hearing loss and suggest that complete blood count and temporal bone imaging be routinely obtained.
  • [MeSH-minor] Adult. Auditory Threshold. Evoked Potentials, Auditory, Brain Stem / physiology. Facial Paralysis / etiology. Female. Humans. Leukemia, Promyelocytic, Acute / complications. Leukemia, Promyelocytic, Acute / therapy. Magnetic Resonance Imaging. Treatment Outcome. Vocal Cord Paralysis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16371856.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


8. Sperr WR, Mitterbauer M, Mitterbauer G, Kundi M, Jäger U, Lechner K, Valent P: Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse. Clin Cancer Res; 2005 Sep 15;11(18):6536-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse.
  • PURPOSE: Recent data suggest that tryptase is produced by blast cells in a group of patients with acute myeloid leukemia (AML).
  • In these patients, serum tryptase levels are elevated at diagnosis and decrease to normal (<15 ng/mL) or near normal values in those achieving complete hematologic remission (CR) after chemotherapy.
  • In 61 patients with de novo AML exhibiting elevated serum tryptase (>15 ng/mL) at diagnosis, tryptase levels were measured serially during and after chemotherapy by a fluoroenzyme immunoassay.
  • Twenty-nine of these 42 patients also entered biochemical remission (BR) defined by a decrease of tryptase levels to normal (<15 ng/mL).
  • Thus, AML relapses occurred in 15 of 29 patients with CR + BR (52%) and in 12 of 13 patients with CR without BR (92%), resulting in a significantly reduced probability of continuous CR for patients with CR without BR (P < 0.05).
  • [MeSH-major] Leukemia, Myeloid / pathology. Neoplasm, Residual / pathology. Serine Endopeptidases / blood
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Recurrence, Local. Oncogene Proteins, Fusion / genetics. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Risk Factors. Survival Analysis. Time Factors. Tryptases

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166430.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CBFbeta-MYH11 fusion protein; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


9. Gale RE, Hills R, Kottaridis PD, Srirangan S, Wheatley K, Burnett AK, Linch DC: No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood; 2005 Nov 15;106(10):3658-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.
  • Fetal liver tyrosine kinase 3 (FLT3) internal tandem duplications (ITDs) are powerful adverse prognostic indicators for relapse in acute myeloid leukemia (AML) but the most efficacious therapy for FLT3/ITD(+) patients is currently unknown.
  • We evaluated outcome according to FLT3/ITD status in 1135 adult patients treated according to United Kingdom Medical Research Council (UK MRC) AML protocols: 141 received an autograft, and 170 received a matched sibling allograft in first complete remission (CR).
  • [MeSH-major] Biomarkers, Tumor. Gene Duplication. Leukemia, Myeloid, Acute / therapy. Stem Cell Transplantation. fms-Like Tyrosine Kinase 3
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Great Britain. Humans. Leukemia, Promyelocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / metabolism. Leukemia, Promyelocytic, Acute / therapy. Male. Meta-Analysis as Topic. Middle Aged. Prognosis. Randomized Controlled Trials as Topic. Recurrence. Transplantation, Autologous. Transplantation, Homologous


10. Siu CW, Au WY, Yung C, Kumana CR, Lau CP, Kwong YL, Tse HF: Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood; 2006 Jul 1;108(1):103-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety.
  • [MeSH-major] Arsenicals / administration & dosage. Drug-Related Side Effects and Adverse Reactions. Electrocardiography. Heart Conduction System / drug effects. Leukemia, Promyelocytic, Acute / diagnosis. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Dose-Response Relationship, Drug. Electrocardiography, Ambulatory. Female. Heart Rate / drug effects. Humans. Male. Middle Aged. Treatment Outcome


11. Zimmerman JJ: Understanding another acute respiratory distress syndrome. Crit Care Med; 2007 Mar;35(3):974-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding another acute respiratory distress syndrome.
  • [MeSH-major] Antineoplastic Agents / toxicity. Chemokines, CXC / physiology. Chemotaxis, Leukocyte / drug effects. Interleukin-8 / physiology. Leukemia, Promyelocytic, Acute / drug therapy. Pulmonary Alveoli / drug effects. Respiratory Distress Syndrome, Adult / chemically induced. Tretinoin / toxicity

  • Genetic Alliance. consumer health - Acute Respiratory Distress Syndrome.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Crit Care Med. 2007 Mar;35(3):879-85 [17235257.001]
  • (PMID = 17421102.001).
  • [ISSN] 0090-3493
  • [Journal-full-title] Critical care medicine
  • [ISO-abbreviation] Crit. Care Med.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CXCL1 protein, human; 0 / Chemokine CXCL1; 0 / Chemokines, CXC; 0 / Interleukin-8; 5688UTC01R / Tretinoin
  •  go-up   go-down


12. Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P, European Acute Promyelocytic Leukemia Group: Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol; 2006 Dec 20;24(36):5703-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.
  • PURPOSE: Several phase II studies have suggested that cytarabine (AraC) was not required in the treatment of newly diagnosed acute promyelocytic leukemia (APL) patients receiving all-trans-retinoic acid (ATRA), an anthracycline, and maintenance therapy, and we aimed at confirming this finding in a randomized trial.
  • PATIENTS AND METHODS: Newly diagnosed APL patients younger than age 60 years with a WBC count of less than 10,000/microL were randomly assigned to receive either ATRA combined with and followed by three daunorubicin (DNR) plus AraC courses and a 2-year maintenance regimen (AraC group) or the same treatment but without AraC (no AraC group).
  • In the AraC and the no AraC groups, the CR rates were 99% and 94% (P = .12), the 2-year cumulative incidence of relapse (CIR) rates were 4.7% and 15.9% (P = .011), the event-free survival (EFS) rates were 93.3% and 77.2% (P = .0021), and survival rates were 97.9% and 89.6% (P = .0066), respectively.
  • CONCLUSION: These results support a role for AraC in addition to ATRA and anthracyclines in the treatment of newly diagnosed APL, at least using DNR at the cumulative dose we used and with the consolidation and maintenance regimens we used.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adult. Daunorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Remission Induction. Survival Analysis. Tretinoin / administration & dosage

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17116939.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


13. Li Y, Chen S, Yang L, Zhou Y, Wu X, Huang M, Geng S: Clonal expanded TCR Vbeta T cells in patients with APL. Hematology; 2005 Apr;10(2):135-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal expanded TCR Vbeta T cells in patients with APL.
  • T-cell receptor Vss gene repertoire and clonality have been studied in patients with leukemia and solid tumors, by assaying the CDR3 size of TCR genes, using RT-PCR and genescan analysis.
  • Few studies have studied leukemia-associated oligoclonal expanded T-cells in leukemia, therefore, the aim of this study was to investigate the distribution and clonal expansion of T-cell receptor, Vss subfamily T-cells in patients with acute promyelocytic leukemia (APL) with t(15;17).
  • The CDR3 of TCR Vbeta24 subfamily genes were analyzed in peripheral blood mononuclear cells from 17 cases with PML-RARalpha+ APL using RT-PCR and genescan technique.
  • The results showed that the number of expressed Vss subfamilies (from 2 to 21 subfamilies) varied in different patients with APL.
  • Clonally expanded T-cells in the Vss subfamilies could be identified in patients with APL in all but two of the cases studied, predominantly in Vbeta10, Vbeta23, Vbeta3 and Vbeta21.
  • In conclusion, skewed distribution and clonal expansion of TCR Vss subfamily T-cells could be found in patients with APL.
  • The clonal expansion of T-cells were considered to be a specific anti-leukemic immune response by host T-cells activated by the leukemia-associated-antigen.
  • [MeSH-major] Gene Expression Regulation, Leukemic / genetics. Gene Rearrangement, T-Lymphocyte / genetics. Genes, T-Cell Receptor beta / genetics. Leukemia, Promyelocytic, Acute / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Chromosomes, Human, Pair 15 / genetics. Chromosomes, Human, Pair 15 / immunology. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 17 / immunology. Female. Humans. Male. Middle Aged. Translocation, Genetic / genetics. Translocation, Genetic / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019459.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


14. Breccia M, Latagliata R, Cannella L, Minotti C, Meloni G, Lo-Coco F: Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation. Haematologica; 2010 May;95(5):853-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation.
  • [MeSH-major] Delayed Diagnosis. Hemorrhage / blood. Hemorrhage / mortality. Leukemia, Promyelocytic, Acute / blood. Leukemia, Promyelocytic, Acute / mortality
  • [MeSH-minor] Adult. Female. Humans. Leukocyte Count. Male. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2008 Aug;35(4):401-9 [18692690.001]
  • [Cites] Haematologica. 2008 Dec;93(12):1918-20 [18945746.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:391-9 [19074116.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3395-402 [18195095.001]
  • [Cites] Br J Haematol. 2000 Mar;108(4):689-95 [10792270.001]
  • [Cites] Eur J Haematol. 2007 Mar;78(3):213-9 [17241371.001]
  • [Cites] Blood. 2009 Feb 26;113(9):1875-91 [18812465.001]
  • (PMID = 20015875.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Letter
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2864399
  •  go-up   go-down


15. Zhan R, Huang HB, Wu SQ, Lin J: [Lysophosphatidic acid acyltransferase β gene expression in newly diagnosed leukemia patients]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec;18(6):1422-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lysophosphatidic acid acyltransferase β gene expression in newly diagnosed leukemia patients].
  • This study was aimed to quantitatively detect the expression level of lysophosphatide acid acyltransferase β (lpaat β) mRNA in leukemia patients so as to provide theoretical basis for the target therapy of lpaat β in leukemia.
  • Real-time fluorescently quantitative PCR was used to detect the relative expression level of lpaat β mRNA to analyze its expression change in various type of leukemia.
  • The results showed that the lpaat β mRNA expression level in acute leukemia (AL) patients was significantly higher than that in normal controls (p < 0.05); lpaat β mRNA expression level in acute myeloid leukemia (AML) patients was significantly higher than that in normal controls (p < 0.05) and was positively correlated with white blood cell count (≥ 20.0 × 10(9)/L) (p < 0.05) and CD34 expression level of leukemia, but was not related with extramedullary infiltration.
  • Except for acute promyelocytic leukemia (APL), the lpaat β mRNA expression level was negatively correlated with chemotherapy sensitivity in chronic myeloid leukemia (AML) patients. lpaat β mRNA expression level in chronic myeloid leukemia (CML) patients was significantly higher than that in normal controls (p < 0.05).
  • lpaat β mRNA expression level in acute lymphoid leukemia (ALL) patients was not higher than that in normal controls (p > 0.05).

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176343.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.3.- / Acyltransferases; EC 2.3.1.52 / 2-acylglycerophosphate acyltransferase
  •  go-up   go-down


16. Arbel Y, Swartzon M, Justo D: QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines. Anticancer Drugs; 2007 Apr;18(4):493-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most patients (n=10; 90.9%) were previously treated with anthracyclines owing to acute leukemias: acute myelogenous leukemia (n=5), acute lymphocytic leukemia (n=3) and acute promyelocytic leukemia (n=2).
  • [MeSH-minor] Adolescent. Adult. Electrocardiography / drug effects. Endometrial Neoplasms / complications. Endometrial Neoplasms / drug therapy. Female. Humans. Middle Aged. Mitoxantrone / adverse effects. Mitoxantrone / therapeutic use. Risk Factors

  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17351403.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Meta-Analysis
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


17. Nasilowska-Adamska B, Majewski M, Seferynska I, Szczepinski A, Tomaszewska A, Prochorec-Sobieszek M, Guz K, Torbicki A, Warzocha K, Marianska B: Predictive value of RT-PCR PML-RARA transcript monitoring for extramedullary relapse of acute promyelocytic leukemia in the pleura, heart and pericardium after allogeneic SCT. Ann Transplant; 2007;12(3):33-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of RT-PCR PML-RARA transcript monitoring for extramedullary relapse of acute promyelocytic leukemia in the pleura, heart and pericardium after allogeneic SCT.
  • BACKGROUND: We report a patient with acute promyelocytic leukemia (APL) relapse in extremely rare sites--the pleura, heart and pericardium without evidence of bone marrow infiltration and with molecular evidence of disease after allogeneic stem cell transplantation (alloSCT).
  • CASE DESCRIPTION: Presented patient underwent alloSCT in second complete hematological and cytogenetic remission with presence of promyelocytic leukemia-retinoic acid receptor A (PML-RARA) detected in reverse transcription-polymerase chain reaction (RT-PCR) with sensitivity of 10(-2).
  • After transplant, this patient remained in complete hematological and cytogenetic remission but nested RT-PCR assays with detection thresholds of 10(-3)/10(-4) were positive for PML-RARA rearranged gene even chimerism tests showed 100% of donor profile.
  • At that time, PML-RARA transcript detected in RT-PCR assay (10(-2)) was positive for the first time after transplant.
  • CONCLUSIONS: We conclude that detection of PML-RARA after alloSCT should be indication insightful diagnosis of medullary or extramedullary (EM) relapse.
  • The imaging techniques of all possible sites of APL EM relapse have to be included.
  • [MeSH-major] Heart Neoplasms / diagnosis. Leukemia, Promyelocytic, Acute / genetics. Oncogene Proteins, Fusion / genetics. Pleural Neoplasms / diagnosis. Sarcoma, Myeloid / diagnosis. Stem Cell Transplantation
  • [MeSH-minor] Adult. Humans. Male. Pericardium. Predictive Value of Tests. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18290568.001).
  • [ISSN] 1425-9524
  • [Journal-full-title] Annals of transplantation
  • [ISO-abbreviation] Ann. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  •  go-up   go-down


18. Dimov ND, Medeiros LJ, Ravandi F, Bueso-Ramos CE: Acute promyelocytic leukemia at time of relapse commonly demonstrates cytogenetic evidence of clonal evolution and variability in blast immunophenotypic features. Am J Clin Pathol; 2010 Mar;133(3):484-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia at time of relapse commonly demonstrates cytogenetic evidence of clonal evolution and variability in blast immunophenotypic features.
  • Despite the success of the current therapy for patients with acute promyelocytic leukemia (APL), relapse occurs in up to 30% of patients.
  • The characteristics of relapsed APL are not well described.
  • We evaluated a group of APL cases at relapse and compared the clinicopathologic, immunophenotypic, molecular, and cytogenetic findings with those at initial diagnosis.
  • From a group of 207 patients with APL, in 38 patients morphologic evidence of relapse developed.
  • The size of the PML-RARalpha fusion transcript was invariable.
  • We conclude that changes in the immunophenotype and cytogenetic evidence of clonal evolution are common in APL at the time of relapse.
  • [MeSH-major] Cytogenetics. Immunophenotyping. Leukemia, Promyelocytic, Acute / pathology. Neoplasm Proteins / genetics. Neoplasm Proteins / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Flow Cytometry. Gene Expression Regulation, Leukemic / genetics. Gene Expression Regulation, Leukemic / immunology. Humans. Infant. Male. Middle Aged. Recurrence. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154288.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


19. Stölzel F, Wermke M, Röllig C, Thiede C, Platzbecker U, Bornhäuser M: Mobilization of PML/RARalpha negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide. Haematologica; 2010 Jan;95(1):171-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mobilization of PML/RARalpha negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide.
  • [MeSH-major] Arsenicals / therapeutic use. Hematopoietic Stem Cell Mobilization / methods. Leukemia, Promyelocytic, Acute / therapy. Oxides / therapeutic use. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Granulocyte Colony-Stimulating Factor / antagonists & inhibitors. Humans. Nuclear Proteins / genetics. Receptors, CXCR4 / antagonists & inhibitors. Receptors, Retinoic Acid / genetics. Secondary Prevention. Transcription Factors / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:391-9 [19074116.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]
  • [Cites] Leukemia. 1999 Dec;13(12):1901-28 [10602411.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] Haematologica. 2009 Sep;94(9):1242-9 [19608685.001]
  • [Cites] Leukemia. 2009 Jan;23(1):43-52 [18987663.001]
  • [Cites] Blood. 2009 Feb 26;113(9):1875-91 [18812465.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5720-6 [19363221.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6206-14 [19050309.001]
  • [CommentOn] Haematologica. 2009 Sep;94(9):1242-9 [19608685.001]
  • (PMID = 19815840.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Arsenicals; 0 / CXCR4 protein, human; 0 / Nuclear Proteins; 0 / Oxides; 0 / Receptors, CXCR4; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor alpha; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 143220-95-5 / PML protein, human; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ PMC2805728
  •  go-up   go-down


20. Kajiguchi T, Yamamoto K, Sawa M, Emi N, Naoe T: Increased erythropoietin level and reticulocyte count during arsenic trioxide therapy. Leukemia; 2005 Apr;19(4):674-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Arsenicals / administration & dosage. Erythropoietin / blood. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / administration & dosage. Reticulocyte Count
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690072.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 11096-26-7 / Erythropoietin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


21. Ozdogu H, Boga C, Yilmaz Z, Sahin FI, Bal N: Long-term colchicine therapy in a patient with Behçet's disease and acute promyelocytic leukemia. Rheumatol Int; 2007 Jun;27(8):763-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term colchicine therapy in a patient with Behçet's disease and acute promyelocytic leukemia.
  • Acute leukemia has seldom been associated with Behçet's disease, although acute promyelocytic leukemia is a particular subtype of leukemia that is often characterized by special cytogenetic abnormalities.
  • We report a male patient with acute promyelocytic leukemia and Behçet's disease who had received long-term treatment with colchicine.
  • To our knowledge, this is the first report of the concomitant occurrence of acute promyelocytic leukemia and Behçet's disease, which suggests that long-term colchicine therapy has a role in the pathogenesis of acute promyelocytic leukemia.
  • [MeSH-major] Behcet Syndrome / drug therapy. Colchicine / adverse effects. Gout Suppressants / adverse effects. Leukemia, Promyelocytic, Acute / complications
  • [MeSH-minor] Adult. Humans. Male. Remission Induction

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • Hazardous Substances Data Bank. COLCHICINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 1992 Sep;16(9):929-35 [1405722.001]
  • [Cites] Ann Med Interne (Paris). 1992;143(7):479-80 [1300872.001]
  • [Cites] Clin Exp Rheumatol. 1984 Apr-Jun;2(2):173-5 [6532622.001]
  • [Cites] Blood. 1994 Jan 1;83(1):10-25 [8274729.001]
  • [Cites] Curr Opin Pharmacol. 2004 Apr;4(2):183-8 [15063364.001]
  • [Cites] Mutat Res. 2001 Aug 22;495(1-2):51-9 [11448642.001]
  • [Cites] Ann Dermatol Venereol. 2002 Dec;129(12):1365-9 [12536172.001]
  • [Cites] South Med J. 2003 Mar;96(3):323-4 [12659376.001]
  • [Cites] J Exp Med. 1989 Jul 1;170(1):15-26 [2664067.001]
  • [Cites] Br J Dermatol. 1997 Aug;137(2):317-8 [9292097.001]
  • [Cites] Mutat Res. 2001 Jun 27;493(1-2):101-14 [11516720.001]
  • [Cites] Am J Physiol. 1991 Oct;261(4 Pt 1):L315-21 [1928366.001]
  • (PMID = 17177066.001).
  • [ISSN] 0172-8172
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Gout Suppressants; SML2Y3J35T / Colchicine
  •  go-up   go-down


22. Chan KH, Yuen SL, Joshua D: A case of all-trans retinoic acid-induced myositis in the treatment of acute promyelocytic leukaemia. Clin Lab Haematol; 2005 Dec;27(6):399-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of all-trans retinoic acid-induced myositis in the treatment of acute promyelocytic leukaemia.
  • The use of all-trans retinoic acid (ATRA) is now standard therapy for the treatment of acute promyelocytic leukaemia (APML).
  • [MeSH-major] Leukemia, Promyelocytic, Acute / complications. Myositis / chemically induced. Tretinoin / adverse effects
  • [MeSH-minor] Adult. Exanthema. Fever. Humans. Male. Steroids / therapeutic use

  • Genetic Alliance. consumer health - Myositis.
  • MedlinePlus Health Information. consumer health - Myositis.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16307543.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Steroids; 5688UTC01R / Tretinoin
  •  go-up   go-down


23. Tsimberidou AM, Estey E, Kantarjian H, Keating MJ, Pierce S, Garcia-Manero G: Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia. Leukemia; 2006 Aug;20(8):1452-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia.
  • [MeSH-major] Cerebral Hemorrhage / chemically induced. Granulocyte Colony-Stimulating Factor / adverse effects. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adult. Female. Filgrastim. Humans. Leukocytosis / chemically induced. Neutrophils / drug effects. Recombinant Proteins

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16728980.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


24. Taguchi A, Takahashi T, Harima Y, Takemoto Y, Ando T, Nomiyama J, Matsubara A, Yujiri T, Tanizawa Y: [All-trans retinoic acid-induced erythema nodosum in acute promyelocytic leukemia]. Rinsho Ketsueki; 2005 Mar;46(3):202-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [All-trans retinoic acid-induced erythema nodosum in acute promyelocytic leukemia].
  • A 24-year-old woman with acute promyelocytic leukemia was treated with all-trans retinoic acid (ATRA) as a remission induction therapy.
  • Although the administration of ATRA was continued until complete remission of the leukemia, the erythema nodosum rapidly disappeared following short-term steroid therapy and no recurrence was observed.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Erythema Nodosum / chemically induced. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / adverse effects
  • [MeSH-minor] Adult. Female. Fever / chemically induced. Humans. Prednisolone / administration & dosage. Recurrence. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447715.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


25. Knipp S, Gattermann N, Schapira M, Käferstein H, Germing U: Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. Leuk Res; 2007 Nov;31(11):1585-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
  • We report on a 42-year-old patient whose relapse of acute promyelocytic leukaemia (APL) included meningeal infiltration.
  • ATO thus crosses the blood-CSF-barrier when administered intravenously, but the concentration in CSF is probably not sufficient for treatment of meningeal leukemia.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenic / cerebrospinal fluid. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416415.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; N712M78A8G / Arsenic; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


26. Au WY, Kwong YL: Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge. J Am Acad Dermatol; 2005 Nov;53(5):890-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 44 patients treated with arsenic trioxide (As2(O3)) for acute promyelocytic leukemia, 11 developed varicella zoster virus (VZV) reactivation (median 56 days [range 15-299]) after treatment.
  • [MeSH-minor] Adolescent. Adult. Aged. Chickenpox. Child. Female. Humans. Male. Middle Aged. Recurrence

  • MedlinePlus Health Information. consumer health - Shingles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243151.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


27. Zhou J, Shi J, Hou J, Cao F, Zhang Y, Rasmussen JT, Heegaard CW, Gilbert GE: Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia. J Thromb Haemost; 2010 Apr;8(4):773-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia.
  • BACKGROUND: Acute promyelocytic leukemia (APL) frequently causes disseminated intravascular coagulation that can worsen with cytotoxic chemotherapy but improve with the therapeutic differentiating agents, all trans retinoic acid (ATRA) and arsenic trioxide (As(2)O(3)).
  • APL cells display tissue factor but the relationship of tissue factor and other procoagulant activity to phosphatidylserine (PS) exposure is largely unknown.
  • METHODS: Lactadherin, a milk protein with stereospecific binding to phosphatidyl-L-serine, was used as a probe for PS exposure on an immortalized APL cell line (NB4) and on the cells of eight patients with APL.
  • RESULTS: Plasma procoagulant activity of NB4 and APL cells increased approximately 15-fold after exposure to etoposide or daunorubicin and decreased 80% after treatment with ATRA or As(2)O(3).
  • Procoagulant activity corresponded to exposed PS on viable APL cells.
  • Excess lactadherin inhibited 80-85% of intrinsic FXase, FVIIa-tissue factor and prothrombinase activities on both NB4 cells and APL cells.
  • CONCLUSIONS: PS is exposed on viable APL cells and is necessary for approximately 80% of procoagulant activity.
  • [MeSH-major] Blood Coagulation. Cell Membrane / metabolism. Leukemia, Promyelocytic, Acute / blood. Phosphatidylserines / metabolism
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / pharmacology. Arsenicals / pharmacology. Blood Coagulation Tests. Cell Differentiation / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Daunorubicin / pharmacology. Etoposide / pharmacology. Factor Xa / metabolism. Female. Flow Cytometry. Humans. Male. Membrane Glycoproteins / metabolism. Microscopy, Confocal. Milk Proteins / metabolism. Oxides / pharmacology. Thrombin / metabolism. Thromboplastin / metabolism. Tretinoin / pharmacology. Young Adult

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20102487.001).
  • [ISSN] 1538-7836
  • [Journal-full-title] Journal of thrombosis and haemostasis : JTH
  • [ISO-abbreviation] J. Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Membrane Glycoproteins; 0 / Milk Proteins; 0 / Oxides; 0 / PAS-6-7 glycoprotein, Bos taurus; 0 / Phosphatidylserines; 5688UTC01R / Tretinoin; 6PLQ3CP4P3 / Etoposide; 9035-58-9 / Thromboplastin; EC 3.4.21.5 / Thrombin; EC 3.4.21.6 / Factor Xa; S7V92P67HO / arsenic trioxide; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


28. Ammatuna E, Montefusco E, Pacilli M, Divona M, Ardiri D, Centonze D, Lo-Coco F: Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone. Leuk Lymphoma; 2009 Jul;50(7):1217-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / chemically induced. Leukemia, Promyelocytic, Acute / complications. Leukemia, Promyelocytic, Acute / drug therapy. Mitoxantrone / adverse effects. Multiple Sclerosis / drug therapy
  • [MeSH-minor] Adult. Arsenicals / therapeutic use. Enzyme Inhibitors / pharmacology. Humans. Male. Oxides / therapeutic use. Remission Induction. Topoisomerase II Inhibitors. Treatment Outcome


29. Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D, Pelosi E, Vitale A, Chierichini A, Cedrone M, Foà R, Lo Coco F, Peschle C, Testa U: TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica; 2005 May;90(5):612-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
  • The present study was designed to evaluate the sensitivity to TRAIL-induced apoptosis in acute myeloblastic leukemias (AML).
  • DESIGN AND METHODS: TRAIL/TRAIL receptor (TRAIL-R) expression and sensitivity to TRAIL-mediated apoptosis were explored in 79 AML patients, including 17 patients with acute promyelocytic leukemia (APL).
  • RESULTS: In non-APL AML we observed frequent expression of TRAIL decoy receptors (TRAIL-R3 and TRAIL-R4), while TRAIL-R1 and TRAIL-R2 expression was restricted to AML exhibiting monocytic features.
  • APL express membrane-bound TRAIL on their surface and exhibit a pattern of TRAIL-R expression similar to that observed in the other types of AML.
  • Before, during and after retinoic acid treatment APL cells are TRAIL-resistant.
  • The induction of granulocytic maturation of APL cells by retinoic acid was associated with a marked decline of TRAIL expression.
  • INTERPRETATION AND CONCLUSIONS: The analysis of experimental APL models (i.e., U937 cells engineered to express PML/RAR-Eo and NB4 cells) provided evidence that PML/RAR-Eo expression was associated with downmodulation of TRAIL-R1 and with resistance to TRAIL-mediated apoptosis.
  • We suggest that AML blasts, including APL blasts, are resistant to TRAIL-mediated apoptosis, a phenomenon seemingly related to the expression of TRAIL decoy receptors on these cells.
  • Finally, APL blasts express membrane-bound TRAIL that could confer an immunologic privilege to these cells.
  • [MeSH-major] Apoptosis / drug effects. Drug Resistance, Neoplasm / genetics. Leukemia, Myeloid / metabolism. Receptors, TNF-Related Apoptosis-Inducing Ligand / physiology. Receptors, Tumor Necrosis Factor / physiology. Tumor Necrosis Factor Decoy Receptors / physiology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antineoplastic Agents / pharmacology. Caspase 3 / analysis. Caspase 8 / analysis. Cell Differentiation / drug effects. Cell Membrane / metabolism. Cytarabine / pharmacology. Etoposide / pharmacology. Female. GPI-Linked Proteins. Granulocytes / drug effects. HL-60 Cells / pathology. Humans. Hydroxyurea / pharmacology. Leukemia, Promyelocytic, Acute / metabolism. Leukemia, Promyelocytic, Acute / pathology. Male. Middle Aged. Monocytes / drug effects. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / physiology. Recombinant Fusion Proteins / pharmacology. Recombinant Fusion Proteins / physiology. Tretinoin / pharmacology. Tumor Cells, Cultured / drug effects. Tumor Stem Cell Assay. U937 Cells / drug effects

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921376.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / GPI-Linked Proteins; 0 / Oncogene Proteins, Fusion; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / Recombinant Fusion Proteins; 0 / TNFRSF10A protein, human; 0 / TNFRSF10B protein, human; 0 / TNFRSF10C protein, human; 0 / TNFRSF10D protein, human; 0 / Tumor Necrosis Factor Decoy Receptors; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; 6PLQ3CP4P3 / Etoposide; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


30. Sanz MA, Montesinos P, Vellenga E, Rayón C, de la Serna J, Parody R, Bergua JM, León A, Negri S, González M, Rivas C, Esteve J, Milone G, González JD, Amutio E, Brunet S, García-Laraña J, Colomer D, Calasanz MJ, Chillón C, Barragán E, Bolufer P, Lowenberg B: Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood; 2008 Oct 15;112(8):3130-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.
  • A previous report of the Programa de Estudio y Tratamiento de las Hemopatías Malignas (PETHEMA) Group showed that a risk-adapted strategy combining all-trans retinoic acid (ATRA) and anthracycline monochemotherapy for induction and consolidation in newly diagnosed acute promyelocytic leukemia results in an improved outcome.
  • [MeSH-major] Anthracyclines / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Disease-Free Survival. Female. Humans. Male. Middle Aged. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18664623.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


31. Guillaume N, Vaida I, Capiod JC, Claisse JF: Acute promyelocytic leukemia with atypical cytologic features. Acta Cytol; 2009 Nov-Dec;53(6):723-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia with atypical cytologic features.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / pathology
  • [MeSH-minor] Adult. Humans. Male. Myeloid Cells / pathology. Peroxidase / metabolism. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20014570.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


32. Al Ameri A, Koller C, Kantarjian H, Ravandi F, Verstovsek S, Borthakur G, Pierce S, Mattiuzzi G: Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer; 2010 Jan 1;116(1):93-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome.
  • BACKGROUND: Acute pulmonary failure during remission induction therapy is a serious complication in patients with acute myeloid leukemia (AML).
  • RESULTS: A total of 120 (8%) patients developed acute pulmonary failure within 2 weeks of the initiation of chemotherapy; 87 of these patients (73%) died during remission induction, whereas 17 (14%) achieved a complete response.
  • The median survival among the 120 patients with early acute pulmonary failure was 3 weeks.
  • Predictive factors for the development of early acute pulmonary failure by multivariate analysis were: male sex (P = .00038), acute promyelocytic leukemia (P = .00003), poor performance status (P = .001), lung infiltrates at diagnosis (P = .000001), and increased creatinine (P = .000005).
  • Patients who had 0 to 1, 2, 3, or 4 to 5 adverse factors were found to have estimated predictive incidences of acute pulmonary failure of 3%, 13%, 23%, and 34%, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / complications. Myelodysplastic Syndromes / drug therapy. Respiratory Insufficiency / chemically induced. Respiratory Insufficiency / complications
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Prognosis. Remission Induction. Risk Factors. Survival Analysis. Time Factors


33. Mallo M, Salido M, Espinet B, Cervera J, Canellas A, Pajuelo JC, Pedro C, Florensa L, Sanz MA, Solé F: Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission? Leuk Res; 2007 Sep;31(9):1315-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Aberrations / drug effects. Chromosomes, Human, Pair 20 / genetics. Leukemia, Promyelocytic, Acute / drug therapy. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Child. DNA, Neoplasm / genetics. Female. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Remission Induction. Survival Rate. Tretinoin / administration & dosage

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17092559.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 5688UTC01R / Tretinoin; ZRP63D75JW / Idarubicin
  •  go-up   go-down


34. Marasca R, Maffei R, Zucchini P, Castelli I, Saviola A, Martinelli S, Ferrari A, Fontana M, Ravanetti S, Torelli G: Gene expression profiling of acute promyelocytic leukaemia identifies two subtypes mainly associated with flt3 mutational status. Leukemia; 2006 Jan;20(1):103-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of acute promyelocytic leukaemia identifies two subtypes mainly associated with flt3 mutational status.
  • Acute promyelocytic leukaemia (APL) is a well-defined disease characterized by a typical morphology of leukaemic cells, the presence of t(15;17) translocation and the unique sensitivity to the differentiating effect of all-trans retinoic acid.
  • Nevertheless, some aspects are variable among APL patients, with differences substantially related to morphological variants, peripheral leukocytes count, the presence of a disseminated intravascular coagulopathy, different PML/RARalpha isoforms (long, variable or short) and Fms-like tyrosine kinase 3 (Flt3) mutations.
  • In order to better define this variability, we investigated the gene expression profiles of 18 APL cases revealing, besides a high uniformity in gene expression pattern, the presence of few robust differences among patients able to identify, by an unsupervised analysis, two major clusters of patients characterized by different phenotypes (hypogranular M3v vs classical M3) and by the presence or absence of Flt3 internal tandem duplications (ITDs).
  • Further supervised analysis confirmed that Flt3 status was the APL parameter best associated with these two subgroups.
  • We identified, between Flt3 wild-type and Flt3-ITDs subsets, 147 differentially expressed genes that were involved in the cytoskeleton organization, in the cell adhesion and migration, in the proliferation and the coagulation/inflammation pathways as well as in differentiation and myeloid granules constitution suggesting a role of Flt3 mutations in the pathogenesis and clinical manifestations of APL.
  • [MeSH-major] Gene Expression Profiling. Leukemia, Promyelocytic, Acute / genetics. Multigene Family. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cluster Analysis. Exons. Female. Humans. Male. Middle Aged. Mutation. Phenotype

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270043.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


35. McMullin MF, Nugent E, Thompson A, Hull D, Jones FG, Grimwade D: Prolonged molecular remission in PML-RARalpha-positive acute promyelocytic leukemia treated with minimal chemotherapy followed by maintenance including the histone deacetylase inhibitor sodium valproate. Leukemia; 2005 Sep;19(9):1676-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged molecular remission in PML-RARalpha-positive acute promyelocytic leukemia treated with minimal chemotherapy followed by maintenance including the histone deacetylase inhibitor sodium valproate.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Histone Deacetylase Inhibitors. Leukemia, Promyelocytic, Acute / drug therapy. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics. Valproic Acid / administration & dosage
  • [MeSH-minor] Adult. Drug Administration Schedule. Drug Therapy, Combination. Enzyme Inhibitors / administration & dosage. Female. Humans. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034463.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


36. Bussaglia E, Guardia R, Nomdedéu JF: A large exon 6 break in V-form acute promyelocytic leukemia: relevance to clinical management. Leukemia; 2007 Nov;21(11):2356-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A large exon 6 break in V-form acute promyelocytic leukemia: relevance to clinical management.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / genetics. Mutation
  • [MeSH-minor] Adult. Bone Marrow / metabolism. Exons. Female. Gene Deletion. Humans. Introns. Models, Biological. Models, Genetic. Polymerase Chain Reaction. Protein Isoforms. Translocation, Genetic. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17568815.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms
  •  go-up   go-down


37. Ostronoff M, Domingues MC, Ostronoff F, Matias C, Florêncio R, Matias K, Souto Maior AP, Sucupira A, Calixto R, Tagliari C: Reduced intensity conditioning allogeneic bone marrow transplantation following central nervous system (CNS) relapse of acute promyelocytic leukemia: evidence for a graft-versus-leukemia effect in the CNS. Am J Hematol; 2006 May;81(5):387-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced intensity conditioning allogeneic bone marrow transplantation following central nervous system (CNS) relapse of acute promyelocytic leukemia: evidence for a graft-versus-leukemia effect in the CNS.
  • [MeSH-major] Bone Marrow Transplantation. Central Nervous System Neoplasms / etiology. Graft vs Leukemia Effect. Leukemia, Promyelocytic, Acute / surgery. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Humans. Male. Recurrence. Remission Induction. Transplantation, Homologous


38. Latagliata R, Carmosino I, Breccia M, Minni A, Testi A, Iorio N, Lo-Coco F, Avvisati G, Petti MC, Mandelli F, Cimino G: Late relapses in acute promyelocytic leukaemia. Acta Haematol; 2007;117(2):106-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late relapses in acute promyelocytic leukaemia.
  • From January 1988 to December 1997, among 53 acute promyelocytic leukaemia patients in 1st complete remission (CR) after 5 years from diagnosis, we observed 5 late relapses (9.4%) after 60, 61, 71, 101 and 155 months from diagnosis; 3 of those late relapses (7.7%) occurred among 39 patients previously treated with all-trans-retinoic acid.
  • All patients achieved a 2nd CR and are still alive: 4 in the 2nd molecular CR after 6, 33, 34 and 115 months; 1 relapsed after 15 months and is now in the 3rd CR.
  • In conclusion, a late relapse occurred in a sizeable fraction of acute promyelocytic leukaemia patients: the high rate of ear involvement might be explained considering the ear as a 'disease sanctuary'.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Cytarabine / administration & dosage. Female. Humans. Idarubicin / administration & dosage. Male. Mastoid / pathology. Mitoxantrone / administration & dosage. Recurrence. Time Factors. Tretinoin / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 S. Karger AG, Basel
  • (PMID = 17135723.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; BZ114NVM5P / Mitoxantrone; ZRP63D75JW / Idarubicin; AIDA protocol
  •  go-up   go-down


39. Patel SP, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovek S, Kantarjian H, Estey E: Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia. Leuk Res; 2006 Mar;30(3):362-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Arrhythmias, Cardiac / chemically induced. Arsenicals / adverse effects. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / adverse effects
  • [MeSH-minor] Adult. African Americans. Female. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Arrhythmia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168477.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA101341
  • [Publication-type] Letter; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


40. Chang JE, Voorhees PM, Kolesar JM, Ahuja HG, Sanchez FA, Rodriguez GA, Kim K, Werndli J, Bailey HH, Kahl BS: Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol; 2009 Mar;27(1):11-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arsenic trioxide (As(2)O(3)) has established clinical activity in acute promyelocytic leukaemia and has pre-clinical data suggesting activity in lymphoid malignancies.
  • The median age was 71, and the majority of enrolled patients had non-Hodgkin's lymphoma (12/17).

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Vitamin C.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 John Wiley & Sons, Ltd.
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1383-91 [9737686.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):772-8 [10328107.001]
  • [Cites] Blood. 1999 Sep 15;94(6):2102-11 [10477740.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2387-401 [15621751.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1687-92 [16130126.001]
  • [Cites] Leuk Lymphoma. 2006 Mar;47(3):521-9 [16396776.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]
  • [Cites] Med Oncol. 2006;23(2):263-72 [16720927.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2465-71 [16651646.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2456-64 [16651647.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2624-9 [16688776.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1105-8 [16870552.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):174-83 [17010047.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]
  • [Cites] Br J Cancer. 1999 Nov;81(5):796-9 [10555748.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1014-22 [10648417.001]
  • [Cites] Br J Haematol. 2001 Mar;112(3):783-6 [11260084.001]
  • [Cites] Oncologist. 2001;6 Suppl 2:17-21 [11331436.001]
  • [Cites] Oncologist. 2001;6 Suppl 2:22-8 [11331437.001]
  • [Cites] Blood. 2001 Aug 1;98(3):805-13 [11468182.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1835-7 [12200700.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3658-68 [12473574.001]
  • [Cites] Leukemia. 2003 Jan;17(1):271-2 [12529694.001]
  • [Cites] Hum Exp Toxicol. 2002 Dec;21(12):675-80 [12540038.001]
  • [Cites] Cancer. 2003 May 1;97(9):2218-24 [12712474.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1028-34 [12676792.001]
  • [Cites] J Nutr Biochem. 2003 Jul;14(7):416-20 [12915223.001]
  • [Cites] Br J Haematol. 2004 May;125(4):470-6 [15142117.001]
  • [Cites] Anal Biochem. 1969 Mar;27(3):502-22 [4388022.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):194-205 [8270977.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7 Suppl):1969s-1975s [8137322.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]
  • [Cites] Blood. 1997 May 1;89(9):3345-53 [9129041.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] Blood. 1997 Jul 15;90(2):562-70 [9226155.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 3;89(23):1789-96 [9392620.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1055-60 [9734658.001]
  • [Cites] Blood. 1999 Jan 1;93(1):268-77 [9864170.001]
  • (PMID = 18668698.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA087718-09; United States / NCI NIH HHS / CA / CA087718-08; United States / NCI NIH HHS / CA / K12 CA087718-07; United States / NCI NIH HHS / CA / K12 CA087718; United States / NCI NIH HHS / CA / CA087718-09; United States / NCI NIH HHS / CA / CA087718-10; United States / NCI NIH HHS / CA / K12 CA087718-10; United States / NCI NIH HHS / CA / K12 CA087718-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; GAN16C9B8O / Glutathione; PQ6CK8PD0R / Ascorbic Acid; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ NIHMS212975; NLM/ PMC2897137
  •  go-up   go-down


41. Dalal BI, Bruyere H, Barnett MJ: Significance of persistent Auer rods and cytogenetic abnormality after first cycle of therapy for acute promyelocytic leukaemia. Br J Haematol; 2007 Jun;137(5):385
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of persistent Auer rods and cytogenetic abnormality after first cycle of therapy for acute promyelocytic leukaemia.
  • [MeSH-major] Bone Marrow Examination. Chromosome Aberrations. Leukemia, Promyelocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Chromosomes, Human, Pair 15. Chromosomes, Human, Pair 17. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Humans. In Situ Hybridization, Fluorescence. Male. Oncogene Proteins, Fusion / genetics. Remission Induction. Translocation, Genetic. Tretinoin / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2008 Sep;142(6):998-1000 [18544082.001]
  • (PMID = 17374141.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


42. Aso N: [Treatment of acute promyelocytic leukemia by using all-trans retinoic acid (ATRA)]. Nihon Naika Gakkai Zasshi; 2005 Sep 10;94(9):1813-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of acute promyelocytic leukemia by using all-trans retinoic acid (ATRA)].
  • [MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16223140.001).
  • [ISSN] 0021-5384
  • [Journal-full-title] Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
  • [ISO-abbreviation] Nippon Naika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 5688UTC01R / Tretinoin
  • [Number-of-references] 10
  •  go-up   go-down


43. Jiao L, Wang SJ, Zhuang JL, Zhao YQ, Zhou DB, Xu Y, Han B, Zhang W, Duan MH, Zou N, Zhu TN, Shen T: [Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct;31(5):555-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].
  • OBJECTIVE: To compare the efficacy and adverse effects between arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) in patients with acute promyelocytic leukemia (APL).
  • METHODS: The clinical data of 71 patients with newly diagnosed APL were retrospectively analyzed.
  • CONCLUSIONS: Both ATO and ATRA have high response rates for newly diagnosed patients with APL.
  • Compared with ATRA, ATO induction therapy has shorter time to achieve CR and less adverse effects, and therefore may be the first-line therapy for APL.
  • [MeSH-major] Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use. Tretinoin / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19968069.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


44. Aljurf M, Al Qurashi F, Al Mohareb F, Sahovic E, Al Sharif F, Al Zahrani H, Al Shanqeeti A, Owaidah T, Iqbal A, Zaidi SZ, Nurgat ZA, Sanz M, Chaudhri N: High efficacy and low toxicity of APL induction with concurrent idarubicin/ATRA followed by a novel and simplified outpatient post-remission therapy using single doses of idarubicin and intermittent ATRA. Med Oncol; 2010 Sep;27(3):702-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High efficacy and low toxicity of APL induction with concurrent idarubicin/ATRA followed by a novel and simplified outpatient post-remission therapy using single doses of idarubicin and intermittent ATRA.
  • Acute promyelocytic leukemia (APL) is one of the most curable myeloid malignancies because of its great sensitivity to all-trans retinoic acid (ATRA) and response to anthracycline therapy.
  • In an attempt to simplify post-remission therapy, deliver adequate dose of anthracycline and reduce treatment related toxicity, we entered 26 consecutively newly diagnosed, previously untreated APL patients in a pilot treatment program consisting of concurrent induction using idarubicin/ATRA followed by an exclusive outpatient post-remission therapy using single dose of idarubicin and intermittent ATRA, every 4 weeks.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Ambulatory Care. Clinical Trials as Topic / statistics & numerical data. Dexamethasone / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Factor VIII / therapeutic use. Female. Fibrinogen / analysis. Fibrinogen / therapeutic use. Hemorrhage / chemically induced. Hemorrhage / drug therapy. Humans. Idarubicin / administration & dosage. Idarubicin / adverse effects. Kaplan-Meier Estimate. Male. Middle Aged. Pilot Projects. Remission Induction. Tretinoin / administration & dosage. Tretinoin / adverse effects. Young Adult

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1992 Nov 1;80(9):2176-81 [1421389.001]
  • [Cites] Blood. 1991 Sep 15;78(6):1413-9 [1884013.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1717-28 [7655004.001]
  • [Cites] Blood. 1993 Dec 1;82(11):3241-9 [8241496.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3015-21 [10556184.001]
  • [Cites] Leukemia. 1993 Nov;7(11):1722-7 [8231241.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1237-43 [14576047.001]
  • [Cites] Blood. 2010 Oct 28;116(17):3171-9 [20644121.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3019-25 [15604216.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):483-90 [9053469.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3141-6 [12384411.001]
  • [Cites] Nouv Rev Fr Hematol. 1984;26(6):371-8 [6597407.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1014-21 [9242531.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3330-7 [9363862.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1247-53 [10942364.001]
  • [Cites] Haematologica. 1987 Mar-Apr;72(2):151-5 [3114070.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] Semin Hematol. 2004 Apr;41(2 Suppl 4):27-32 [15190513.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1202-6 [7858250.001]
  • (PMID = 19669610.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / cryoprecipitate coagulum; 5688UTC01R / Tretinoin; 7S5I7G3JQL / Dexamethasone; 9001-27-8 / Factor VIII; 9001-32-5 / Fibrinogen; ZRP63D75JW / Idarubicin
  •  go-up   go-down


45. Fan LP, Shen JZ: [Expression of Maf-b mRNA in de novo leukemia patients and its clinical significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1147-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of Maf-b mRNA in de novo leukemia patients and its clinical significance].
  • This study was aimed to quantitatively detect the level of maf-b mRNA in leukemia patients and evaluate its clinical significance.
  • The expression change of maf-b mRNA in various types of leukemia was analyzed.
  • The results showed that maf-b mRNA expression level in acute myeloid leukemia (AML) patients was lower than that in normal group (p<0.01) and positively correlated with white blood cell count (p<0.01) and the expression of CD34 (p<0.01).
  • There was no correlation between maf-b mRNA expression level and chemotherapy response in AML patients except for acute promyelocytic leukemia (APL).
  • Maf-b mRNA expression levels in acute lymphoid leukemia (ALL) and chronic myeloid leukemia (CML) patients were also lower than that in normal group (p<0.01).

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129249.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / MafB Transcription Factor; 0 / RNA, Messenger
  •  go-up   go-down


46. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H: Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol; 2009 Feb 1;27(4):504-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
  • PURPOSE: We examined the outcome of patients with newly diagnosed acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) with or without gemtuzumab ozogamicin (GO) but without traditional cytotoxic chemotherapy.
  • PATIENTS AND METHODS: From February 2002 to March 2008, 82 patients with APL were treated with a combination of ATRA plus ATO.
  • From July 2007, the second cohort of 17 patients received ATRA and ATO concomitantly on day 1.
  • Monitoring for PML-RARA fusion gene was conducted after induction and throughout consolidation and follow-up.
  • CONCLUSION: The combination of ATRA and ATO (with or without GO) as initial therapy for APL was effective and safe and can substitute chemotherapy-containing regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / administration & dosage. Arsenicals / administration & dosage. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged. Oxides / administration & dosage. Polymerase Chain Reaction. Remission Induction. Survival Rate. Treatment Outcome. Tretinoin / administration & dosage

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19075265.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 0 / gemtuzumab; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ PMC4881307
  •  go-up   go-down


47. Takitani K, Koh M, Inoue A, Kawakami C, Kuno T, Tamai H: Pharmacokinetics of all-trans retinoic acid in adults and children with acute promyelocytic leukemia. Am J Hematol; 2006 Sep;81(9):720-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of all-trans retinoic acid in adults and children with acute promyelocytic leukemia.
  • [MeSH-major] Aging / metabolism. Antineoplastic Agents / pharmacokinetics. Leukemia, Promyelocytic, Acute / metabolism. Tretinoin / pharmacokinetics
  • [MeSH-minor] Adult. Biological Availability. Central Nervous System / drug effects. Child. Humans. Remission Induction

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16838336.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


48. Feusner J, Gregory JJ Jr: Update on the management of pediatric acute promyelocytic leukemia. Clin Adv Hematol Oncol; 2006 Nov;4(11):854-5; author reply 855-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the management of pediatric acute promyelocytic leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Component Transfusion. Leukemia, Promyelocytic, Acute / therapy
  • [MeSH-minor] Adult. Child. Child, Preschool. Female. Hemorrhage / blood. Hemorrhage / etiology. Hemorrhage / mortality. Hemorrhage / therapy. Humans. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Clin Adv Hematol Oncol. 2006 Apr;4(4):263-5 [16728936.001]
  • (PMID = 17193721.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


49. Boban A, Radman I, Zadro R, Dubravcic K, Maretic T, Civljak R, Lisic M, Begovac J: Acute promyelocytic leukemia after whole brain irradiation of primary brain lymphoma in an HIV-infected patient. Eur J Med Res; 2009 Jan 28;14(1):42-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia after whole brain irradiation of primary brain lymphoma in an HIV-infected patient.
  • The occurrence of acute promyelocytic leukemia (APL) in HIV-infected patients has been reported in only five cases.
  • Due to a very small number of reported HIV/APL patients who have been treated with different therapies with the variable outcome, the prognosis of APL in the setting of the HIV-infection is unclear.
  • Here, we report a case of an HIV-patient who developed APL and upon treatment entered a complete remission.
  • In 2006, prompted by a sudden neutropenia, we carried out a set of diagnostic procedures, revealing APL.
  • The last follow-up 14 months later, showed sustained molecular APL remission.
  • In conclusion, we demonstrated that a complete molecular APL remission in an HIV-patient was achieved by using reduced-intensity treatment.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / radiotherapy. HIV Infections / complications. Leukemia, Promyelocytic, Acute / etiology. Leukemia, Radiation-Induced / etiology. Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Anti-Retroviral Agents / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active / methods. Bisexuality. Humans. Idarubicin / therapeutic use. Male. Remission Induction. Tretinoin


50. Santamaría C, Chillón MC, Fernández C, Martín-Jiménez P, Balanzategui A, García Sanz R, San Miguel JF, González MG: Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. Haematologica; 2007 Mar;92(3):315-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.
  • BACKGROUND AND OBJECTIVES: The detection of PML-RARalpha by real-time polymerase chain reaction (RQ-PCR) is becoming an important tool for monitoring minimal residual disease (MRD) in patients with acute promyelocytic leukemia (APL).
  • DESIGN AND METHODS: Follow-up samples from 145 APL patients treated with the PETHEMA protocols were evaluated by the RQ-PCR protocol (Europe Against Cancer program) and by the RT-PCR method (BIOMED-1 Concerted Action).
  • During maintenance therapy and out-of treatment, all patients with >10 PML-RARalpha normalized copy number (NCN) (n=19) relapsed while all patients with <1 NCN at the end of the study remained in hematologic remission (p<0.0001).
  • INTERPRETATION AND CONCLUSIONS: Based on the information provided by RQ-PCR in samples obtained after the end of consolidation and subsequently, a relapse risk stratification could be established for APL patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Leukemia, Promyelocytic, Acute / drug therapy. Oncogene Proteins, Fusion / blood. Polymerase Chain Reaction / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Clinical Trials as Topic / statistics & numerical data. Computer Systems. DNA, Complementary / genetics. Disease-Free Survival. Drug Monitoring. Female. Follow-Up Studies. Gene Dosage. Humans. Idarubicin / administration & dosage. Kaplan-Meier Estimate. Leukocyte Count. Male. Middle Aged. Multicenter Studies as Topic / statistics & numerical data. Neoplasm, Residual. Predictive Value of Tests. RNA, Messenger / blood. RNA, Neoplasm / blood. Recurrence. Remission Induction. Risk Assessment. Salvage Therapy. Sensitivity and Specificity. Survival Analysis. Tretinoin / administration & dosage

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2007 Mar;92(3):289-91 [17339175.001]
  • (PMID = 17339180.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Complementary; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin; ZRP63D75JW / Idarubicin; AIDA protocol
  •  go-up   go-down


51. Kelaidi C, Ades L, Chevret S, Sanz M, Guerci A, Thomas X, de Botton S, Raffoux E, Rayon C, Fegueux N, Bordessoule D, Rigal-Huguet F, Link H, Stoppa A, Vekhoff A, Meyer-Monard S, Castaigne S, Dombret H, Degos L, Fenaux P: Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials). Leukemia; 2006 May;20(5):905-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).
  • [MeSH-major] Anthracyclines / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / administration & dosage
  • [MeSH-minor] Adult. Aged. Arsenicals / therapeutic use. Combined Modality Therapy. Europe. Female. Humans. Male. Middle Aged. Oxides / therapeutic use. Prognosis. Recurrence. Risk Factors. Treatment Outcome

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16541143.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


52. Wang D, Ke XY, Wang J, Xu F, Hu YF: [Correlation between MDR1 genetic polymorphism and prognosis in acute myeloid leukemia]. Zhonghua Yi Xue Za Zhi; 2007 May 29;87(20):1384-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between MDR1 genetic polymorphism and prognosis in acute myeloid leukemia].
  • OBJECTIVE: To assess the correlation of the multidrug resistance-1 (MDR1) gene single nucleotide polymorphisms (SNP) C1236T, G2677T/A and C3435T with the outcome of induction chemotherapy in patients with de novo acute myeloid leukemia (AML).
  • [MeSH-major] Leukemia, Myeloid / genetics. P-Glycoprotein / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Base Sequence. DNA Mutational Analysis. Female. Gene Frequency. Genotype. Humans. Leukemia, Erythroblastic, Acute / drug therapy. Leukemia, Erythroblastic, Acute / genetics. Leukemia, Erythroblastic, Acute / pathology. Leukemia, Megakaryoblastic, Acute / drug therapy. Leukemia, Megakaryoblastic, Acute / genetics. Leukemia, Megakaryoblastic, Acute / pathology. Leukemia, Monocytic, Acute / drug therapy. Leukemia, Monocytic, Acute / genetics. Leukemia, Monocytic, Acute / pathology. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Leukemia, Myelomonocytic, Acute / drug therapy. Leukemia, Myelomonocytic, Acute / genetics. Leukemia, Myelomonocytic, Acute / pathology. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / pathology. Male. Middle Aged. P-Glycoproteins. Prognosis. Remission Induction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785057.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / P-Glycoprotein; 0 / P-Glycoproteins
  •  go-up   go-down


53. Klein SK, Biemond BJ, van Oers MH: Two cases of isolated symptomatic myocarditis induced by all-trans retinoic acid (ATRA). Ann Hematol; 2007 Dec;86(12):917-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Idarubicin / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Male. Methotrexate / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage

  • Genetic Alliance. consumer health - Myocarditis.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1996 Aug 15;88(4):1390-8 [8695858.001]
  • [Cites] Am J Hematol. 2002 Sep;71(1):62-4 [12221682.001]
  • [Cites] Drug Saf. 1998 Apr;18(4):273-9 [9565738.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2712-8 [9763554.001]
  • [Cites] Br J Haematol. 2005 May;129(3):444-5 [15842672.001]
  • [Cites] Ann Intern Med. 1992 Aug 15;117(4):292-6 [1637024.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • (PMID = 17619879.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 5688UTC01R / Tretinoin; BZ114NVM5P / Mitoxantrone; E7WED276I5 / 6-Mercaptopurine; YL5FZ2Y5U1 / Methotrexate; ZRP63D75JW / Idarubicin
  • [Number-of-references] 7
  • [Other-IDs] NLM/ PMC2040172
  •  go-up   go-down


54. Sanz MA, Labopin M, Gorin NC, de la Rubia J, Arcese W, Meloni G, Bacigalupo A, Alessandrino P, Carreras E, Iriondo A, Novitzky N, Jacobs P, Bandini G, Lo-Coco F, Frassoni F, Rocha V, Acute Leukemia Working Party (ALWP) of European Cooperative Group for Blood and Marrow Transplantation (EBMT): Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplant; 2007 Apr;39(8):461-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation.
  • We performed a survey of the European Cooperative Group for Blood and Marrow Transplantation to analyze the outcome of 625 acute promyelocytic leukemia (APL) patients transplanted with auto- or allogeneic-hematopoietic stem cell transplantation (autoHSCT, alloHSCT) after 1993, in first (CR1) or in second complete remission (CR2).
  • Leukemia-free survival (LFS) at 5 years in CR1 was 69% for 149 patients autografted and 68% for 144 patients allografted, whereas in CR2, LFS was 51% in 195 autoHSCT and 59% in 137 alloHSCT recipients, respectively.
  • In conclusion, HSCT still appears to have a role in APL, especially for patients in CR2.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Promyelocytic, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Animals. Disease-Free Survival. Female. Follow-Up Studies. Health Surveys. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Survival Analysis. Time Factors. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17322930.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


55. Fujiwara M, Satou N, Izumi N, Shibasaki Y, Higashimura M, Tsukada N, Koike T: [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute]. Gan To Kagaku Ryoho; 2007 Nov;34(11):1793-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
  • Fifty-seven patients with acute myelogenous leukemia (AML) received the following treatment in our hospital between May 1992 and April 2005.
  • Group A: combination of enocitabine, daunorubicin, 6-mercaptopurine riboside and prednisolone (BHAC-DMP) for remission induction, BHAC-DMP or idarubicin (IDR)+cytarabine (Ara-C) for first consolidation, combination of prednisolone, Ara-C, mitoxantrone and etoposide (PAME) for second consolidation, and PAME for late intensification; Group B: IDR+Ara-C for remission induction, PAME for first consolidation, and high-dose Ara-C+mitoxantrone for second consolidation; Group C (acute promyelocytic leukemia, APL) : all-trans retinoic acid (ATRA) for remission induction, BHAC-DMP or IDR+Ara-C for first consolidation, and PAME for second consolidation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adult. Aged. Cytarabine / administration & dosage. Cytarabine / analogs & derivatives. Daunorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Evidence-Based Medicine. Female. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Prednisone / administration & dosage. Quality of Life. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030012.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; ZRP63D75JW / Idarubicin; ZS7284E0ZP / Daunorubicin; BHAC-DMPV protocol; PAME protocol
  •  go-up   go-down


56. Kammerer S, Roth RB, Hoyal CR, Reneland R, Marnellos G, Kiechle M, Schwarz-Boeger U, Griffiths LR, Ebner F, Rehbock J, Cantor CR, Nelson MR, Braun A: Association of the NuMA region on chromosome 11q13 with breast cancer susceptibility. Proc Natl Acad Sci U S A; 2005 Feb 8;102(6):2004-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NuMA-retinoic acid receptor alpha fusion proteins have been described in acute promyelocytic leukemia.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Nuclear. Disease Susceptibility. Female. Genetic Markers. Genotype. Humans. Linkage Disequilibrium. Middle Aged. Nuclear Matrix-Associated Proteins. Polymorphism, Genetic. Risk Factors. Statistics as Topic

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Coriell Cell Repositories. culture/stock collections - Coriell Cell Repositories .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2004 Jan 22;23(3):665-78 [14737102.001]
  • [Cites] Ann Hum Genet. 2002 Nov;66(Pt 5-6):393-405 [12485472.001]
  • [Cites] Int J Cancer. 2004 Sep 10;111(4):543-7 [15239132.001]
  • [Cites] Genome Res. 2004 Aug;14(8):1664-8 [15289484.001]
  • [Cites] Cell. 1980 Nov;22(2 Pt 2):489-99 [7004645.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] Science. 1990 Nov 30;250(4985):1233-8 [1978757.001]
  • [Cites] EMBO J. 1991 Nov;10(11):3351-62 [1915296.001]
  • [Cites] J Cell Biol. 1992 Mar;116(6):1303-17 [1541630.001]
  • [Cites] J Cell Biol. 1992 Mar;116(6):1395-408 [1541636.001]
  • [Cites] Mol Biol Cell. 1992 Nov;3(11):1259-67 [1457830.001]
  • [Cites] J Cell Biol. 1993 Feb;120(4):947-57 [8432734.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1505-9 [8108437.001]
  • [Cites] Science. 1994 Sep 30;265(5181):2088-90 [8091231.001]
  • [Cites] Science. 1994 Oct 7;266(5182):66-71 [7545954.001]
  • [Cites] Ann N Y Acad Sci. 1995 Sep 30;768:250-2 [8526358.001]
  • [Cites] Cancer Surv. 1995;25:27-65 [8718512.001]
  • [Cites] J Cell Sci. 1996 Jan;109 ( Pt 1):45-56 [8834789.001]
  • [Cites] Cell. 1996 Nov 1;87(3):447-58 [8898198.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):843-54 [10548311.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):1023-32 [10566559.001]
  • [Cites] Exp Cell Res. 2000 Apr 10;256(1):140-9 [10739661.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] J Biol Chem. 2000 Oct 13;275(41):31979-85 [10913114.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):581-4 [11136232.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):91-9 [11253062.001]
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]
  • [Cites] J Cell Sci. 2001 Dec;114(Pt 24):4557-65 [11792820.001]
  • [Cites] Genes Dev. 2002 Mar 1;16(5):571-82 [11877377.001]
  • [Cites] J Immunol. 2002 Apr 1;168(7):3608-16 [11907126.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):650-4 [12426569.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16871-4 [12475937.001]
  • [Cites] J Cell Sci. 2003 Feb 1;116(Pt 3):571-83 [12508117.001]
  • [Cites] Nat Genet. 2003 Mar;33 Suppl:238-44 [12610533.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4066-71 [12646697.001]
  • [Cites] Am J Hum Genet. 2003 Nov;73(5):1162-9 [14574645.001]
  • [Cites] Science. 2003 Oct 24;302(5645):643-6 [14576434.001]
  • [Cites] Trends Genet. 2003 Nov;19(11):615-22 [14585613.001]
  • [Cites] Mayo Clin Proc. 1997 Jan;72(1):54-65 [9005288.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1063-5 [9067272.001]
  • [Cites] Exp Cell Res. 1997 May 25;233(1):21-4 [9184071.001]
  • [Cites] Nat Genet. 1997 Sep;17(1):109-13 [9288109.001]
  • [Cites] Science. 1997 Nov 28;278(5343):1580-1 [9411782.001]
  • [Cites] J Exp Med. 1998 Feb 16;187(4):587-600 [9463409.001]
  • [Cites] J Natl Cancer Inst. 1998 Apr 1;90(7):512-8 [9539246.001]
  • [Cites] FEBS Lett. 1999 Feb 26;445(2-3):338-42 [10094485.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8906-10 [15604251.001]
  • [Cites] Am J Hum Genet. 2004 Jun;74(6):1175-82 [15122511.001]
  • (PMID = 15684076.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Genetic Markers; 0 / NUMA1 protein, human; 0 / Nuclear Matrix-Associated Proteins; 0 / Nuclear Proteins
  • [Other-IDs] NLM/ PMC548529
  •  go-up   go-down


57. Hall MJ, Li L, Wiernik PH, Olopade OI: BRCA2 mutation and the risk of hematologic malignancy. Leuk Lymphoma; 2006 Apr;47(4):765-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Breast Neoplasms / complications. Breast Neoplasms / genetics. Family Health. Female. Heterozygote. Humans. Leukemia, Promyelocytic, Acute / complications. Leukemia, Promyelocytic, Acute / genetics. Middle Aged. Risk

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886281.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  •  go-up   go-down


58. Wang FR, Lou YQ, Lu DP: [A clinical pharmacokinetic study of multi-dose oral tetra-arsenic tetra-sulfide combination therapy in acute promyelocytic leukemia]. Zhonghua Nei Ke Za Zhi; 2005 Oct;44(10):730-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinical pharmacokinetic study of multi-dose oral tetra-arsenic tetra-sulfide combination therapy in acute promyelocytic leukemia].
  • OBJECTIVE: To study the pharmacokinetics of multi-dose oral tetra-arsenic tetra-sulfide (As(4)S(4)) in acute promyelocytic leukemia (APL) patients and its major side effects.
  • CONCLUSION: Multi-dose oral As(4)S(4) is safe and has been relatively well tolerated in APL patients in spite of the tendency of its retention in some tissues after long time administration.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Arsenicals / pharmacokinetics. Leukemia, Promyelocytic, Acute / drug therapy. Sulfides / pharmacokinetics
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Area Under Curve. Arsenic / metabolism. Female. Hair / chemistry. Humans. Male

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16255875.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Sulfides; N712M78A8G / Arsenic
  •  go-up   go-down


59. Farhat M, Venugopal P: Long-term remission of extramedullary relapse from acute promyelocytic leukemia after treatment with arsenic trioxide, intrathecal chemotherapy, and brain irradiation. Clin Adv Hematol Oncol; 2007 Apr;5(4):320-3; discussion 323-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term remission of extramedullary relapse from acute promyelocytic leukemia after treatment with arsenic trioxide, intrathecal chemotherapy, and brain irradiation.
  • [MeSH-major] Arsenicals / administration & dosage. Cranial Irradiation. Ear Neoplasms / therapy. Leukemia, Myelomonocytic, Acute. Oxides / administration & dosage. Sarcoma, Myeloid / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Daunorubicin / administration & dosage. Humans. Injections, Spinal. Male. Remission Induction. Tretinoin / administration & dosage

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17607291.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide; ZS7284E0ZP / Daunorubicin
  • [Number-of-references] 48
  •  go-up   go-down


60. Chillón MC, Santamaría C, García-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Marín L, Caballero MD, Vidriales MB, Ramos F, Bernal T, Díaz-Mediavilla J, García de Coca A, Peñarrubia MJ, Queizán JA, Giraldo P, San Miguel JF, González M: Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. Haematologica; 2010 May;95(5):745-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.
  • BACKGROUND: Internal tandem duplications of the FLT3 gene (FLT3-ITDs) are frequent in patients with acute promyelocytic leukemia (APL), however its clinical impact remains controversial.
  • DESIGN AND METHODS: We analyzed the prognostic significance of FLT3-ITD mutant level and size, as well as FLT3-D835 point mutations, PML-RARalpha expression and other predictive factors in 129 APL patients at diagnosis enrolled on the Spanish LPA96 (n=43) or LPA99 (n=86) PETHEMA trials.
  • Moreover, patients with initial normalized copy number (NCN) of PML-RARalpha transcripts less than the 25(th) percentile had adverse clinical features and shorter 5-year RFS (P<0.0001) and OS (P=0.004) compared to patients with higher NCN.
  • Multivariate analysis showed that long FLT3-ITD (P=0.001), low PML-RARalpha levels (P=0.004) and elevated WBC counts (>10x10(9)/L) (P=0.018) were independent predictors for shorter RFS.
  • CONCLUSIONS: In conclusion, FLT3-ITD size and PML-RARalpha transcript levels at diagnosis could contribute to improve the risk stratification in APL.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Leukemia, Promyelocytic, Acute / diagnosis. Leukemia, Promyelocytic, Acute / genetics. Oncogene Proteins, Fusion / antagonists & inhibitors. Oncogene Proteins, Fusion / genetics. Tandem Repeat Sequences / genetics. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Adult. Biomarkers, Tumor / genetics. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Point Mutation / genetics. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Jun 15;93(12):4131-43 [10361110.001]
  • [Cites] Haematologica. 2007 Mar;92(3):315-22 [17339180.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1153-60 [15889156.001]
  • [Cites] Haematologica. 2005 Nov;90(11):1493-501 [16266896.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3768-76 [16105978.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):790-7 [16418499.001]
  • [Cites] Haematologica. 2006 Mar;91(3):311-6 [16531253.001]
  • [Cites] Blood. 2006 May 1;107(9):3724-6 [16368883.001]
  • [Cites] Leukemia. 2006 Nov;20(11):2074-6 [16990788.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Blood. 2002 Jul 1;100(1):59-66 [12070009.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1532-42 [12176867.001]
  • [Cites] Leukemia. 2002 Nov;16(11):2185-9 [12399960.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4372-80 [12393388.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2521-8 [12468436.001]
  • [Cites] Blood Rev. 2003 Jun;17(2):71-97 [12642121.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1857-65 [12750176.001]
  • [Cites] Haematologica. 2007 Jul;92(7):994-5 [17606455.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1078-84 [17975017.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2776-84 [17957027.001]
  • [Cites] Haematologica. 2008 Dec;93(12):1797-805 [18815192.001]
  • [Cites] Haematologica. 1999 May;84(5):405-12 [10329918.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3015-21 [10556184.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1247-53 [10942364.001]
  • [Cites] Leukemia. 2001 Jul;15(7):1072-80 [11455976.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7233-9 [11585760.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1206-16 [12973844.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2746-55 [12842988.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4413-22 [14645432.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2474-86 [14562124.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1237-43 [14576047.001]
  • [Cites] Hematol J. 2004;5(3):239-46 [15167911.001]
  • [Cites] J Clin Oncol. 1983 Nov;1(11):710-9 [6668489.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):78-85 [9440726.001]
  • [Cites] Br J Haematol. 2005 Jul;130(2):196-202 [16029447.001]
  • (PMID = 20133893.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC2864380
  •  go-up   go-down


61. Nishioka C, Ikezoe T, Yang J, Yokoyama A: Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1. Apoptosis; 2010 Jul;15(7):795-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1.
  • We previously showed that the MEK inhibitor AZD6244 induced apoptosis in acute myelogenous leukemia (AML) HL60 cells.
  • Moreover, we found that blockade of mTORC1 by RAD001 synergistically enhanced the action of AZD6244 in leukemia cells.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / antagonists & inhibitors. Apoptosis. Benzimidazoles / pharmacology. Leukemia, Promyelocytic, Acute / enzymology. MAP Kinase Signaling System / drug effects. Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors. Phosphoproteins / antagonists & inhibitors. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors
  • [MeSH-minor] Adult. Aged. Cell Cycle / drug effects. Cell Proliferation / drug effects. Down-Regulation. Everolimus. Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors. Female. HL-60 Cells. Humans. Male. Middle Aged. Multiprotein Complexes. Myeloid Cell Leukemia Sequence 1 Protein. Proteins. Sirolimus / analogs & derivatives. Sirolimus / pharmacology. TOR Serine-Threonine Kinases. Transcription Factors / antagonists & inhibitors

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20221697.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AZD 6244; 0 / Adaptor Proteins, Signal Transducing; 0 / Benzimidazoles; 0 / EIF4EBP1 protein, human; 0 / Multiprotein Complexes; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Phosphoproteins; 0 / Protein Kinase Inhibitors; 0 / Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Transcription Factors; 0 / mechanistic target of rapamycin complex 1; 9HW64Q8G6G / Everolimus; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


62. Viola A, Pagano L, Laudati D, D'Elia R, D'Amico MR, Ammirabile M, Palmieri S, Prossomariti L, Ferrara F: HFE gene mutations in patients with acute leukemia. Leuk Lymphoma; 2006 Nov;47(11):2331-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HFE gene mutations in patients with acute leukemia.
  • In the present study, we investigated the allelic frequency of HFE gene mutations in 154 adult patients with acute leukemia (AL) [107 acute myeloid leukemia (AML), 20 acute promyelocytic leukemia (APL) and 27 acute lymphoblastic leukemia (ALL)].
  • No difference was found between controls and AML or APL patients, whereas the H63D mutation was significantly more frequent in ALL than controls (44% vs. 25%, P = 0.04; OR = 2.37; 95% CI = 1.05 - 5.36).
  • In conclusion, our data demonstrate a correlation between the presence of the H63D mutation and the occurrence of ALL in adult patients.
  • [MeSH-major] Histocompatibility Antigens Class I / genetics. Leukemia / genetics. Membrane Proteins / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Aspartic Acid / genetics. Female. Genotype. Histidine / genetics. Humans. Male. Middle Aged. Mutation / genetics

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Nov;47(11):2269-70 [17107894.001]
  • (PMID = 17107905.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HFE protein, human; 0 / Histocompatibility Antigens Class I; 0 / Membrane Proteins; 30KYC7MIAI / Aspartic Acid; 4QD397987E / Histidine
  •  go-up   go-down


63. Liang JY, Wu DP, Liu YJ, Ma QF, Gong JX, Zhu MQ, Xue YQ, Chen ZX: [The clinical and laboratory features of acute promyelocytic leukemia: an analysis of 513 cases]. Zhonghua Nei Ke Za Zhi; 2008 May;47(5):389-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical and laboratory features of acute promyelocytic leukemia: an analysis of 513 cases].
  • OBJECTIVE: To investigate the clinical and laboratory features of acute promyelocytic leukemia (APL).
  • METHODS: 513 APL patients in the last two decades were retrospectively analyzed in this research.
  • RESULTS: The median age of the APL patients was 33 years old and the ratio of male and female was 1.21:1.
  • Before treatment, the median level of WBC was 4.3 x 10(9)/L and the detection rate of abnormal promyelocyte on blood film was 85.8%; with immunophenotypic detection, the expression levels of CD117, CD34, HLA-DR, CD7, CD14 and CD19 in APL were found to be lower and the expression levels of CD2, CD33 and MPO higher than those in other subtypes of acute myelocytic leukemia (AML) (both P < 0.01).
  • Specific abnormal chromosome t (15;17) was detected in 91.7% of the patients, of whom 75.9% had standard translocation of t (15;17), being the most common one and 15.8% of the patients had t (15;17) with additional abnormal chromosome.
  • With molecular biological detection, PML/RARalpha fusion gene positive rate was 99.6%.
  • In a relatively long clinical follow-up, we found that the complete remission (CR) rate in APL patients was 84.7%, incidence of DIC was 13.4% and five-year survival rate was 30.7%.
  • CONCLUSIONS: Comprehensive evaluation of MICM could be of important significance in the diagnosis and prognosis judgment for APL patients.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / immunology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged, 80 and over. Child. Cytogenetic Analysis. Female. Flow Cytometry. Humans. Immunophenotyping. Male. Middle Aged. Retrospective Studies. Sex Distribution. Young Adult

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953948.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


64. Wang L, Li Y, Wang PP, Lu XL, Wang BX: [Role of P27(Kip1) and TGF-beta1 in APL cell apoptosis induced by As(2)O(3)]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr;17(2):324-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of P27(Kip1) and TGF-beta1 in APL cell apoptosis induced by As(2)O(3)].
  • The aim of study was to investigate the effects of arsenic trioxide (As(2)O(3)) on cell cycle and apoptosis of APL cells, as well as changes of P27(Kip1), endogenous TGF-beta1, cyclin E and bcl-2, and to explore the relationship between expression of P27(Kip1) and apoptosis induced by As(2)O(3).
  • The apoptosis and cell cycle changes of APL cells treated with As(2)O(3) were detected by morphology and flow cytometry respectively, the protein and mRNA expressions of P27(Kip1), TGF-beta1, cyclin E and BCL-2 were measured by immunohistochemistry and RT-PCR.
  • The results indicated that As(2)O(3) induced APL cell apoptosis in vitro, and cell cycle was arrested at G(1) phase.
  • Protein and mRNA expressions of P27(Kip1) and TGF-beta1 of APL cells after treatment with As(2)O(3) increased, accompanying with decrease of cyclin E, bcl-2 protein and mRNA expressions.
  • It is concluded that the apoptosis of APL cells is induced by As(2)O(3), and the cell cycle is arrested at G(1) phase.
  • Apoptosis of APL cells induced by As(2)O(3) may be caused by up-regulating TGF-beta1 and P27(Kip1), which is antagonistic to cyclin E and BLC-2, leading to arrest of cell cycle at G(1) phase.

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19379560.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Arsenicals; 0 / CDKN1B protein, human; 0 / Oxides; 0 / Transforming Growth Factor beta1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


65. Abolfazl M, Fatemeh I, Hamid A, Mojtaba G, Alireza MJ, Ali MM: Specific chromosomal abnormalities in patients with acute nonlymphocytic leukemia from the Islamic Republic of Iran. Asian Pac J Cancer Prev; 2006 Jul-Sep;7(3):447-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific chromosomal abnormalities in patients with acute nonlymphocytic leukemia from the Islamic Republic of Iran.
  • Cytogenetic analysis performed at diagnosis is considered to be the most valuable prognostic factor in acute non-lymphocytic leukemia (ANLL), a very heterogeneous disease.
  • Some 14 were classified as M1, 20 as M2, 19 as M3 , 3 as M4, 1 as M5 and 1 as M6.
  • The most common chromosome rearrangements were t(15;17), t( 8;21) and t(9;22).
  • [MeSH-major] Chromosome Aberrations. Leukemia, Myeloid, Acute / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Iran / epidemiology. Karyotyping. Leukemia, Promyelocytic, Acute / epidemiology. Leukemia, Promyelocytic, Acute / genetics. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059342.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Thailand
  •  go-up   go-down


66. Matsuo K, Kiura K, Tabata M, Uchida A, Hotta K, Niiya D, Kubonishi S, Ogino A, Fujiwara Y, Nakajima H, Shinagawa K, Ishimaru F, Ueoka H, Tanimoto M: Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution. Am J Hematol; 2006 May;81(5):349-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution.
  • A crude incidence rate ratio was calculated by ratio of crude incidence rate in our subject to population-based incident rate of all leukemia (ICD: C91-95) in the same region.
  • Three cases of acute promyelocytic leukemia (APL) occurred during gefitinib treatment, and these patients' past treatment histories are presented herein.
  • All presented a normal karyotype with positive PML-RARalpha in RT-PCR, indicating submicroscopic translocation.
  • They responded well to APL treatments, including all-trans-retinoic acid.
  • The crude incident rate ratio was 639.9 (95% confidence interval: 131.6-1,878.9, P < 0.0001) when the APL incidence in this cohort was compared to all leukemia cases in the general population in the same district in Japan.
  • Thus we had three cases of secondary APL patients within the gefitinib-treated NSCLC cohort.
  • Although we cannot exclude an effect of past exposure of other cytotoxic agents and radiotherapy as a cause of APL, APL inducibility of gefitinib should be clarified in the further study.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Non-Small-Cell Lung / drug therapy. Leukemia, Promyelocytic, Acute. Lung Neoplasms / drug therapy. Quinazolines / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cluster Analysis. Female. Humans. Incidence. Male. Middle Aged. Receptor, Epidermal Growth Factor / antagonists & inhibitors


67. Advani AS, Hunger SP, Burnett AK: Acute leukemia in adolescents and young adults. Semin Oncol; 2009 Jun;36(3):213-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukemia in adolescents and young adults.
  • In the treatment of acute leukemia age is a predictor of response.
  • Thus, in acute lymphoblastic leukemia (ALL) there is a clearly poorer treatment outcome after puberty, while in acute myeloid leukaemia (AML), which is more common in older adults, age is a continuous variable with poorer outcomes in each successive decade.
  • Adolescents may be included in pediatric or adult-oriented treatment protocols.
  • Here we discuss the outcome of acute leukemia in adolescents and young adults, particularly with respect to whether they respond similarly to children or other adults.
  • [MeSH-major] Leukemia, Myeloid, Acute. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Leukemia, Promyelocytic, Acute. Stem Cell Transplantation. Survival Rate

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19460579.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 66
  •  go-up   go-down


68. Fukushima S, Terasaki M, Tajima Y, Shigemori M: Granulocytic sarcoma: an unusual complication of acute promyelocytic leukemia causing cerebellar hemorrhage. Case report. J Neurosurg; 2006 Dec;105(6):912-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma: an unusual complication of acute promyelocytic leukemia causing cerebellar hemorrhage. Case report.
  • Granulocytic sarcomas are rare tumors that occur primarily in patients with acute myelogenous leukemia or other myeloproliferative disorders, are seldom seen in patients with acute promyelocytic leukemia (APL), and have never been reported to occur in the cerebellum.
  • The authors describe the case of a patient with APL who harbored a hemorrhagic granulocytic sarcoma in the cerebellum.
  • Bone marrow samples showing infiltration by leukemic blast cells and data from hematological tests led to a diagnosis of APL.
  • Although no cytogenetic abnormality was present, fluorescence in situ hybridization detected a chimeric fusion of PML and RARA.
  • This is the first report to document a granulocytic sarcoma in the cerebellum as the primary presentation in a patient with APL and abnormal coagulation.
  • Although central nervous system complications in patients with APL are rare, the data in this case highlight the need for individualized treatment when such conditions occur.
  • [MeSH-major] Cerebellar Neoplasms / etiology. Cerebral Hemorrhage / etiology. Leukemia, Promyelocytic, Acute / complications. Sarcoma, Myeloid / etiology
  • [MeSH-minor] Adult. Bone Marrow / pathology. Cerebellar Ataxia / etiology. Cerebellum / pathology. Chimera / genetics. Female. Gene Fusion / genetics. Granulocyte Precursor Cells / pathology. Humans. Inclusion Bodies / pathology. Karyotyping. Magnetic Resonance Imaging. Receptors, Retinoic Acid / genetics

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405265.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha
  •  go-up   go-down


69. Suzuki R, Onizuka M, Kojima M, Shimada M, Tsuboi K, Ogawa Y, Kawada H, Ando K: Infrequent hypermethylation of WIF-1 promoter in BCR/ABL-negative myeloproliferative disorders. Tokai J Exp Clin Med; 2007 Dec;32(4):131-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Wnt inhibitory factor-1 (WIF-1) is a negative regulator of Wnt signaling that is frequently downregulated by hypermethylation of the WIF-1 promoter in acute promyelocytic leukemia (APL) and other malignancies.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Chronic Disease. Cohort Studies. CpG Islands / genetics. Female. Fusion Proteins, bcr-abl. Humans. Male. Methylation. Middle Aged. Molecular Sequence Data. Mutation. Promoter Regions, Genetic. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21318952.001).
  • [ISSN] 2185-2243
  • [Journal-full-title] The Tokai journal of experimental and clinical medicine
  • [ISO-abbreviation] Tokai J. Exp. Clin. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Repressor Proteins; 0 / WIF1 protein, human; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


70. Wang T, Qiu JY, Yu CF, Ma XL, Jia XP, Wang YP, Liu HX, Lin YH, Tong CR, Lu DP: [Analysis of variant translocation der ins (17; 15) in patient with APL by G-banding technique and interphase fluorescence in situ hybridization]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun;17(3):537-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of variant translocation der ins (17; 15) in patient with APL by G-banding technique and interphase fluorescence in situ hybridization].
  • To investigate the biological characteristics of the variant translocation der ins (17;15) in a patient with acute promyelocytic leukemia (APL), the conventional G-banding technique, interphase fluorescence in situ hybridization (int-FISH), RT-PCR, gene scanning, gene sequence and flow cytometry were performed.
  • The results indicated that the variant translocation der ins (17, 15) observed by G banding technique was a rare type, the int-FISH assay by using dual-color pml/raralpha fusion probes confirmed the cytogenetic findings.
  • The detection results of other molecular methods demonstrated the existence of the whole pml/raralpha fusion gene, while this case had insertion variant translocation.
  • In conclusion, the variant translocation der ins (17;.
  • 15) is rare type in APL, its incidence is lower, several signal types in detection of int-FISH were observed and the combination chemotherapy for this patient showed more obvious efficacy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549359.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


71. Sivera R, Bataller L, Martínez J, Villanueva V: Mesial temporal sclerosis as a complication of hematologic cancer. J Neurol; 2009 Oct;256(10):1759-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brain Diseases / etiology. Brain Diseases / pathology. Leukemia, Promyelocytic, Acute / complications. Lymphoma, Non-Hodgkin / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Temporal Lobe / pathology
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Sclerosis / drug therapy. Sclerosis / etiology. Sclerosis / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2007 Sep 18;69(12):1236-44 [17875912.001]
  • [Cites] Neurology. 2002 Nov 12;59(9 Suppl 5):S21-6 [12428028.001]
  • [Cites] Neurology. 1998 May;50(5):1377-82 [9595990.001]
  • [Cites] Neurology. 2003 May 13;60(9):1534-6 [12743248.001]
  • [Cites] Epilepsia. 2003 Jan;44(1):131-4 [12581241.001]
  • [Cites] J Child Neurol. 2006 Oct;21(10):861-6 [17005102.001]
  • [Cites] Bone Marrow Transplant. 2003 May;31(10):919-22 [12748669.001]
  • (PMID = 19434437.001).
  • [ISSN] 1432-1459
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


72. Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, Perot C, Lai JL, Ballerini P, Mazingue F, Fasola S, Dehée A, Bellman F, Adam M, Labopin M, Douay L, Leverger G, Preudhomme C, Landman-Parker J: High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol; 2006 Apr 1;24(10):1507-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.
  • PURPOSE: To determine whether minimal residual disease (MRD) measured by Wilms' tumor gene 1 (WT1) expression is a prognostic marker in pediatric acute myeloid leukemia (AML), we quantified WT1 transcript by real-time quantitative-polymerase chain reaction in 92 AML at diagnosis and during follow-up.
  • PATIENTS AND METHODS: Patients (median age, 6 years; cytogenetics, favorable 27%, intermediate 59%, poor 13%) were treated between 1995 and 2002 and enrolled in Leucémie aiguë Myéloblastique Enfant (LAME) 89/91, LAME 99 pilot study and Acute Promyelocytic Leukemia French collaborative protocols.
  • The WT1 values were significantly higher (P = .01) in favorable cytogenetics and lower (P < .0001) in M5-FAB subtype, 11q23 rearrangements (P < .001), and infants (P = .003) and demonstrate a strong correlation with fusion transcript AML1-ETO, PML-RARalpha expression.
  • [MeSH-major] Genes, Wilms Tumor. Leukemia, Myeloid, Acute / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Core Binding Factor Alpha 2 Subunit / genetics. Female. Gene Dosage. Humans. Infant. Infant, Newborn. Male. Multivariate Analysis. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics. RNA, Messenger / analysis. Recurrence. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575000.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  •  go-up   go-down


73. Altintaş A, Paşa S, Cil T, Kaplan MA, Ayyildiz O: Retinoic acid syndrome subsequent to the first dose of all trans retinoic acid. J Emerg Med; 2008 Nov;35(4):456-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / adverse effects
  • [MeSH-minor] Adult. Female. Humans

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18554851.001).
  • [ISSN] 0736-4679
  • [Journal-full-title] The Journal of emergency medicine
  • [ISO-abbreviation] J Emerg Med
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


74. British Committee for Standards in Haematology, Milligan DW, Grimwade D, Cullis JO, Bond L, Swirsky D, Craddock C, Kell J, Homewood J, Campbell K, McGinley S, Wheatley K, Jackson G: Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol; 2006 Nov;135(4):450-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines on the management of acute myeloid leukaemia in adults.
  • [MeSH-major] Leukemia, Myeloid / diagnosis. Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adult. Age Factors. Aged. Antibiotic Prophylaxis. Clinical Trials as Topic. Female. Hematopoietic Stem Cell Transplantation. Humans. Leukemia, Promyelocytic, Acute / diagnosis. Leukemia, Promyelocytic, Acute / therapy. Male. Middle Aged. Opportunistic Infections / prevention & control. Patient Care Team / standards. Pregnancy. Pregnancy Complications, Neoplastic / therapy. Prognosis

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054678.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300133
  • [Publication-type] Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 181
  •  go-up   go-down


75. Ciccone M, Rigolin GM, Viglione GM, Borrelli M, Serino ML, Cuneo A: Thrombosis of the cerebral veins and sinuses in acute promyelocytic leukemia after all-trans retinoic acid treatment: a case report. Blood Coagul Fibrinolysis; 2008 Oct;19(7):721-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thrombosis of the cerebral veins and sinuses in acute promyelocytic leukemia after all-trans retinoic acid treatment: a case report.
  • Thrombosis of the cerebral veins or sinuses is a rare cerebrovascular disorder, which seldom represents a complication of acute promyelocytic leukemia.
  • We report a case of a 35-year-old woman affected by acute promyelocytic leukemia, who developed massive thrombosis of the cerebral sinuses and veins when she was in complete morphological and molecular remission after all-trans retinoic acid and idarubicin treatment.
  • [MeSH-major] Cerebral Hemorrhage / chemically induced. Leukemia, Promyelocytic, Acute / drug therapy. Sinus Thrombosis, Intracranial / chemically induced. Thrombosis / chemically induced. Tretinoin / adverse effects
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Idarubicin / administration & dosage

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18832917.001).
  • [ISSN] 0957-5235
  • [Journal-full-title] Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • [ISO-abbreviation] Blood Coagul. Fibrinolysis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5688UTC01R / Tretinoin; ZRP63D75JW / Idarubicin
  •  go-up   go-down


76. Kawasaki K, Akaike H, Miyauchi A, Ouchi K: Sivelestat relieves respiratory distress refractory to dexamethasone in all-trans retinoic acid syndrome: a report of two cases. Eur J Haematol; 2006 Nov;77(5):448-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment with all-trans retinoic acid (ATRA) improves the prognosis of patients with acute promyelocytic leukemia (APL), but ATRA syndrome may occur as a possible fatal side effect, especially in cases refractory to medication or involving pulmonary hemorrhage.
  • We describe two patients with APL who suffered from intracranial hemorrhage.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Glycine / analogs & derivatives. Leukemia, Promyelocytic, Acute / complications. Respiratory Distress Syndrome, Adult / chemically induced. Respiratory Distress Syndrome, Adult / drug therapy. Serine Proteinase Inhibitors / administration & dosage. Sulfonamides / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. GLYCINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Care Med. 2003 Apr;31(4 Suppl):S189-94 [12682439.001]
  • [Cites] AJR Am J Roentgenol. 2002 Feb;178(2):475-80 [11804921.001]
  • [Cites] Leuk Lymphoma. 2000 May;37(5-6):605-10 [11042521.001]
  • [Cites] N Engl J Med. 2000 May 4;342(18):1334-49 [10793167.001]
  • [Cites] Blood. 2000 Jan 1;95(1):90-5 [10607690.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2712-8 [9763554.001]
  • [Cites] Dig Dis Sci. 1995 Oct;40(10):2177-83 [7587785.001]
  • [Cites] Clin Lab Haematol. 1994 Dec;16(4):371-4 [7736715.001]
  • [Cites] Blood. 1990 Jun 1;75(11):2112-7 [2189506.001]
  • [Cites] Arch Intern Med. 1988 Jun;148(6):1409-12 [3132124.001]
  • [Cites] Pulm Pharmacol Ther. 2004;17(5):271-9 [15477122.001]
  • [Cites] Crit Care Med. 2004 Aug;32(8):1695-702 [15286546.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1404-12 [15084614.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Oct;158(4):1302-5 [9769296.001]
  • (PMID = 16930140.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Serine Proteinase Inhibitors; 0 / Sulfonamides; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; 7S5I7G3JQL / Dexamethasone; DWI62G0P59 / sivelestat; TE7660XO1C / Glycine
  • [Other-IDs] NLM/ PMC1618807
  •  go-up   go-down


77. Kakimoto T, Takahashi Y, Watanabe H, Matsuzawa M, Sanada Y, Suzuki K, Mihara A, Yoshida S, Nakazato T: Primary multiple cerebral invasion in acute promyelocytic leukemia dramatically worsened by all-trans retinoic acid. Leuk Res; 2010 May;34(5):e137-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary multiple cerebral invasion in acute promyelocytic leukemia dramatically worsened by all-trans retinoic acid.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Brain Neoplasms / drug therapy. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / adverse effects
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Anti-Bacterial Agents / therapeutic use. Bacillus cereus. Bacterial Infections / drug therapy. Brain Abscess / drug therapy. Cytarabine / therapeutic use. Female. Humans. Idarubicin / therapeutic use. Injections, Spinal. Magnetic Resonance Imaging. Methotrexate / administration & dosage

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20015546.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; YL5FZ2Y5U1 / Methotrexate; ZRP63D75JW / Idarubicin
  •  go-up   go-down


78. Brown C, Opat S: An unusual case of indigestion: persistence of phagocytosed Auer rods in acute promyelocytic leukaemia. Br J Haematol; 2006 Apr;133(2):112
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of indigestion: persistence of phagocytosed Auer rods in acute promyelocytic leukaemia.
  • [MeSH-major] Inclusion Bodies / pathology. Leukemia, Promyelocytic, Acute / pathology. Phagocytosis
  • [MeSH-minor] Adult. Bone Marrow Cells / pathology. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16611301.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


79. Saito H, Monoe K, Kanno Y, Takahashi A, Rai T, Irisawa A, Ohira H: Two cases of primary biliary cirrhosis complicated by acute leukemia. Intern Med; 2007;46(9):561-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of primary biliary cirrhosis complicated by acute leukemia.
  • She was diagnosed as having acute lymphoid leukemia (ALL) by bone marrow examination.
  • Seven years later, she was diagnosed as having acute promyelocytic leukemia (APL) by bone marrow examination.
  • To date, there have been no reports of PBC complicated by acute leukemia.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / complications. Liver Cirrhosis, Biliary / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blotting, Western. CREST Syndrome / complications. Dihydrolipoyllysine-Residue Acetyltransferase / metabolism. Fatal Outcome. Female. Humans. Liver / pathology. Middle Aged

  • Genetic Alliance. consumer health - Primary biliary cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17473489.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 2.3.1.12 / Dihydrolipoyllysine-Residue Acetyltransferase
  •  go-up   go-down


80. Otero L, Terra B, Diniz C, Abdelhay E, Fernandez Tde S: Dicentric t(8;13)(q10;q10) as an additional chromosomal abnormality in a case of acute promyelocytic leukemia with very poor outcome. Leuk Lymphoma; 2009 Feb;50(2):287-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dicentric t(8;13)(q10;q10) as an additional chromosomal abnormality in a case of acute promyelocytic leukemia with very poor outcome.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 13 / genetics. Chromosomes, Human, Pair 8 / genetics. Leukemia, Promyelocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / pathology
  • [MeSH-minor] Female. Humans. Prognosis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19197738.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


81. Dogan E, Erkoc R, Sayarlioglu H, Alici S, Dilek I, Alici O: Fatal lactic acidosis due to leukemic transformation in a patient with non-Hodgkin's lymphoma: case report. Adv Ther; 2005 Sep-Oct;22(5):443-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was no reason other than leukemia-such as infection, circulatory failure, or drug use-for the development of severe LA.
  • [MeSH-major] Acidosis, Lactic / etiology. Leukemia, Promyelocytic, Acute / complications. Lymphoma, Large B-Cell, Diffuse / complications
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Lactic Acidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418152.001).
  • [ISSN] 0741-238X
  • [Journal-full-title] Advances in therapy
  • [ISO-abbreviation] Adv Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Fujita H, Nakaya A, Kato J, Tachibana T, Takemura S, Hyo R, Kawano T, Tanaka M, Taguchi J, Maruta A, Fujimaki K, Kanamori H, Ishigatsubo Y: [Hematopoietic stem cell transplantation in the second or later complete remission in acute promyelocytic leukemia initially treated with all-trans retinoic acid]. Rinsho Ketsueki; 2005 Oct;46(10):1095-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hematopoietic stem cell transplantation in the second or later complete remission in acute promyelocytic leukemia initially treated with all-trans retinoic acid].
  • Despite the use of all-trans retinoic acid (ATRA) as the first-line treatment for acute promyelocytic leukemia (APL), relapse occurs in about 20% of cases.
  • Most relapsing APL patients can achieve second remission (CR2) following ATRA combined with chemotherapy or arsenic trioxide.
  • We analyzed the outcomes for 8 APL patients initially treated using ATRA, who relapsed, achieved CR2 and underwent auto-SCT (n = 4) or allo-SCT (n = 4).
  • The results for auto-SCT are favorable in patients with MRD-negative APL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Promyelocytic, Acute / therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Retrospective Studies. Treatment Outcome


83. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE: Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol; 2010 Jun 1;28(16):2739-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
  • PURPOSE: To determine the clinical relevance of mutations in the CCAAT/enhancer binding protein alpha (CEBPA) gene in acute myeloid leukemia (AML) and to examine factors that might modify prognostic impact.
  • PATIENTS AND METHODS: The entire CEBPA coding sequence was screened in 1,427 young adult patients with AML, excluding acute promyelocytic leukemia, using denaturing high-performance liquid chromatography and direct sequencing.
  • [MeSH-major] CCAAT-Enhancer-Binding Protein-alpha / genetics. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / mortality. Mutation. Nuclear Proteins / genetics. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow Transplantation. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Gene Expression Regulation, Leukemic. Genetic Predisposition to Disease. Genetic Testing / methods. Genotype. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Prospective Studies. Risk Assessment. Sex Factors. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20439648.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Protein-alpha; 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


84. Qiu HR, Li JY, Miao KR, Wang R, Zhang JF, Xu W: [A case of acute promyelocytic leukemia with variant t(5;17) and trisomy 22]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug;25(4):430-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of acute promyelocytic leukemia with variant t(5;17) and trisomy 22].
  • OBJECTIVE: To report a case of acute promyelocytic leukemia (APL) with variant t(5;17)(q35;q21) and to explore its laboratory and clinical features.
  • RESULTS: The karyotype of the patient was 47, XY, t(5;17), +22.
  • FISH analysis showed PML-RAR aleph negative but 77% cells had a rearrangement or duplication of the RAR aleph gene.
  • M-FISH confirmed the abnormalities are of chromosomes 5 and 17 rearrangement and trisomy 22.
  • CONCLUSION: Variant t(5;17) giving rise to the fusion gene of NPM-RAR aleph rarely occurs in APL patients.
  • [MeSH-major] Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 22. Chromosomes, Human, Pair 5. Gene Rearrangement. Karyotyping. Leukemia, Promyelocytic, Acute / genetics. Trisomy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Oncogene Proteins, Fusion / genetics. Translocation, Genetic. Young Adult

  • Genetic Alliance. consumer health - Chromosome 22, Trisomy.
  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18683144.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


85. Mao L, Wang H, Cheng Y, Wang Y, Chen Z, Jie J: Occurrence of t(15;17)(q22;q21) and t(9;22)(q34;q11) in a patient with acute promyelocytic leukemia. Leuk Lymphoma; 2009 Mar;50(3):466-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of t(15;17)(q22;q21) and t(9;22)(q34;q11) in a patient with acute promyelocytic leukemia.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 15. Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 22. Chromosomes, Human, Pair 9. Cytogenetic Analysis. Female. Humans

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19266352.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


86. Jeddi R, Kacem K, Ben Neji H, Mnif S, Gouider E, Aissaoui L, Ben Amor R, Ben Lakhal R, Ben Abid H, Belhadjali Z, Meddeb B: Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia. Hematology; 2008 Jun;13(3):142-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia.
  • BACKGROUND: The combination of all-trans-retinoic acid (ATRA) and chemotherapy has made acute promyelocytic leukemia (APL) a highly curable leukemia.
  • We aimed at identifying factors that could predict complications caused by ATRA during induction treatment of APL.
  • PATIENTS: Forty-two patients with confirmed APL (by t(15;17) and/or PML/RARA) treated at our institution (University hospital of Tunis) between January 1998 and June 2006 using two consecutive protocols: European APL93 trial (24 patients) until February 2004 and Spanish PETHEMA LPA99 trial (18 patients) more recently.
  • Thirty-three patients achieved CR (78.57%):18/24 (75%) in APL93 versus 15/18 (83%) in LPA99.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Survival Analysis. Treatment Outcome


87. McCormack E, Bruserud O, Gjertsen BT: Review: genetic models of acute myeloid leukaemia. Oncogene; 2008 Jun 19;27(27):3765-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review: genetic models of acute myeloid leukaemia.
  • The use of genetically engineered mice (GEM) have been critical in understanding disease states such as cancer, and none more so than acute myelogenous leukaemia (AML), a disease characterized by over 100 distinct chromosomal translocations.
  • A substantial proportion of cases exhibiting recurrent reciprocal translocations at diagnosis, such as t(8;21) or t(15;17) have been exhaustively studied and are currently employed in clinical diagnosis.
  • Furthermore, little emphasis has been paid to the effect of chromosomal translocations other than recurrent genetic abnormalities, with no models reflecting the multiple abnormalities observed in high-risk cases of AML accounting for 8-10% of adult AML.
  • [MeSH-major] Animals, Genetically Modified / genetics. Leukemia, Myeloid, Acute / genetics. Models, Genetic
  • [MeSH-minor] Animals. Chromosome Aberrations. Disease Models, Animal. Exons. Humans. Leukemia, Promyelocytic, Acute / genetics. Mice. Mice, Transgenic. Prognosis


88. Wahlin A, Billström R, Björ O, Ahlgren T, Hedenus M, Höglund M, Lindmark A, Markevärn B, Nilsson B, Sallerfors B, Brune M: Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study. Eur J Haematol; 2009 Aug;83(2):99-107
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
  • In 1997-2003, a protocol for treatment of acute myeloid leukaemia (AML) (except promyelocytic leukaemia) was activated in four Swedish health care regions covering 50% of the national population.
  • Outcome after relapse was poor with median time to death 163 d and 4-yr survival rate 17%.
  • Three conclusions were: (i) these data reflect treatment results in a minimally selected population-based cohort of adult AML patients <60 yr old;.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / therapy. Population Surveillance. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Adolescent. Adult. Cytogenetic Analysis. Female. Follow-Up Studies. Humans. Male. Middle Aged. Recurrence. Risk Factors. Survival Rate. Sweden. Time Factors. Transplantation, Homologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19385987.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


89. Machner B, Neppert B, Paulsen M, Hofmann C, Sander T, Helmchen C: Pseudotumor cerebri as a reversible side effect of all-trans retinoic acid treatment in acute promyelocytic leukaemia. Eur J Neurol; 2008 Jul;15(7):e68-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudotumor cerebri as a reversible side effect of all-trans retinoic acid treatment in acute promyelocytic leukaemia.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Promyelocytic, Acute / drug therapy. Pseudotumor Cerebri / chemically induced. Tretinoin / adverse effects
  • [MeSH-minor] Acetazolamide / therapeutic use. Adult. Anticonvulsants / therapeutic use. Female. Humans. Idarubicin / therapeutic use. Obesity. Spinal Puncture

  • Genetic Alliance. consumer health - Pseudotumor cerebri.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. ACETAZOLAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18452541.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin; O3FX965V0I / Acetazolamide; ZRP63D75JW / Idarubicin
  •  go-up   go-down


90. Su YC, Dunn P, Shih LY, Kuo MC, Chang H, Wu JH, Lin TL, Wang PN, Tang TC, Hung YS: Retinoic acid syndrome in patients following the treatment of acute promyelocytic leukemia with all-trans retinoic acid. Chang Gung Med J; 2009 Sep-Oct;32(5):535-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoic acid syndrome in patients following the treatment of acute promyelocytic leukemia with all-trans retinoic acid.
  • BACKGROUND: Retinoic acid syndrome (RAS) is a potentially lethal complication during all-trans retinoic acid (ATRA) treatment of acute promyelocytic leukemia (APL).
  • METHODS: We retrospectively analyzed 102 patients diagnosed with APL between August 1993 and December 2007 at Chang Gung Memorial Hospital, Taiwan.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Leukocyte Count. Male. Middle Aged. Oncogene Proteins, Fusion / genetics. Retrospective Studies. Syndrome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19840511.001).
  • [ISSN] 2309-835X
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin
  •  go-up   go-down


91. Moon H, Lee S, Huh J, Chung WS: Characteristics of acute myeloid leukemia without HLA-DR expression. Korean J Lab Med; 2007 Oct;27(5):313-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of acute myeloid leukemia without HLA-DR expression.
  • BACKGROUND: HLA-DR negativity is known to be useful for distinguishing acute promyelocytic leukemia (APL) from other subtypes of AML, but non-APL cases without HLA-DR antigen expression have been reported.
  • The purpose of this study was to evaluate and compare the characteristics of APL, HLA-DR negative non-APL, and HLA-DR positive non-APL cases.
  • RESULTS: Among the 114 AML patients, HLA-DR antigen was not expressed in 39 (34%), including 24 non-APL (62%) and 15 APL patients (38%).
  • The HLA-DR negative non-APL group showed higher leukocyte counts and positive rate of CD19 expression than did APL group (P<0.05).
  • The remaining laboratory findings were not statistically different between the HLA-DR negative non-APL and APL groups.
  • CD34 expression was more frequent in the HLA-DR positive non-APL group than in the HLA-DR negative non-APL group and APL group.
  • Of the 24 patients with HLA-DR negative non-APL, 7 patients had disseminated intravascular coagulation and 2 patients showed morphologic features similar to those of APL.
  • CONCLUSIONS: CD19 expression and leukocyte count may be helpful for differentiating HLA-DR negative non-APL from APL.
  • [MeSH-major] HLA-DR Antigens / metabolism. Leukemia, Myeloid, Acute / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD19 / metabolism. Antigens, CD34 / metabolism. Child. Child, Preschool. Female. Humans. Immunophenotyping. Leukocyte Count. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094594.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD34; 0 / HLA-DR Antigens
  •  go-up   go-down


92. Lee HY, Kim KM, Kang MH, Kang JH, Kang KM, Lee GW: Concurrent craniospinal radiotherapy and intrathecal chemotherapy in patient with acute promyelocytic leukemia second relapsed in central nervous system (CNS) following allogeneic stem cell transplantation. J Neurooncol; 2006 Aug;79(1):73-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent craniospinal radiotherapy and intrathecal chemotherapy in patient with acute promyelocytic leukemia second relapsed in central nervous system (CNS) following allogeneic stem cell transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / therapy. Cranial Irradiation. Leukemia, Promyelocytic, Acute / therapy. Neoplasm Recurrence, Local / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Injections, Spinal. Male


93. Wang Y, Fang M, Jing Y, Li J, Jiang F, Wang Y: Derivative (7)t(7;8): The sole karyotype abnormality in acute promyelocytic leukemia with PML/RARA rearrangement identified by RT-PCR and sequence analysis. Leuk Res; 2009 Jul;33(7):e55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Derivative (7)t(7;8): The sole karyotype abnormality in acute promyelocytic leukemia with PML/RARA rearrangement identified by RT-PCR and sequence analysis.
  • [MeSH-major] Chromosomes, Human, Pair 7 / genetics. Chromosomes, Human, Pair 8 / genetics. Gene Rearrangement. Leukemia, Promyelocytic, Acute / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Chromosome Banding. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19162322.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  •  go-up   go-down


94. Tsai WH, Hsu HC, Lin CC, Ho CK, Kou YR: Role of interleukin-8 and growth-regulated oncogene-alpha in the chemotactic migration of all-trans retinoic acid-treated promyelocytic leukemic cells toward alveolar epithelial cells. Crit Care Med; 2007 Mar;35(3):879-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of interleukin-8 and growth-regulated oncogene-alpha in the chemotactic migration of all-trans retinoic acid-treated promyelocytic leukemic cells toward alveolar epithelial cells.
  • OBJECTIVE: Although all-trans retinoic acid (ATRA) can treat acute promyelocytic leukemia (APL), it also causes retinoic acid syndrome with presentations similar to acute respiratory distress syndrome.
  • We investigated the role of interleukin (IL)-8 and growth-regulated oncogene (GRO)-alpha in the chemotactic transmigration of ATRA-treated NB4 (ATRA-NB4) APL cells toward A549 alveolar epithelial cells.
  • CONCLUSIONS: IL-8 and GRO-alpha secreted from alveolar epithelial cells play an important role in the cell-cell interaction involved in the chemotactic transmigration of ATRA-treated APL cells toward alveolar epithelial cells.
  • [MeSH-major] Antineoplastic Agents / toxicity. Chemokines, CXC / physiology. Chemotaxis, Leukocyte / drug effects. Interleukin-8 / physiology. Leukemia, Promyelocytic, Acute / drug therapy. Pulmonary Alveoli / drug effects. Respiratory Distress Syndrome, Adult / chemically induced. Tretinoin / toxicity

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Crit Care Med. 2007 Mar;35(3):974-5 [17421102.001]
  • (PMID = 17235257.001).
  • [ISSN] 0090-3493
  • [Journal-full-title] Critical care medicine
  • [ISO-abbreviation] Crit. Care Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CXCL1 protein, human; 0 / Chemokine CXCL1; 0 / Chemokines, CXC; 0 / Interleukin-8; 5688UTC01R / Tretinoin
  •  go-up   go-down


95. Lin J, Han LX, Qian J, Wang YL, Qian Z, Yang XF, Sheng XJ: [Quantification of PML/RAR alpha fusion gene transcripts in patients with acute promyelocytic leukemia by using real-time quantitative PCR]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Jun;25(3):319-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Quantification of PML/RAR alpha fusion gene transcripts in patients with acute promyelocytic leukemia by using real-time quantitative PCR].
  • OBJECTIVE: To establish and evaluate a real time quantitative PCR (RQ-PCR) method for detection and quantification the PML/RAR alpha fusion gene transcripts in patients with acute promyelocytic leukemia (APL).
  • METHODS: Three pairs of primers and TaqMan probe were designed for detecting the most frequent PML/RAR alpha transcripts (L-form, S-form and V-form) and normal ABL was used as an internal control.
  • A real time PCR condition was established to detect PML/RAR alpha and ABL positive templates with a series of dilutions.
  • To evaluate this assay, bone marrow samples from 6 APL patients were detected.
  • The median absolute and normalized amount of PML/RAR alpha fusion gene transcripts were 4.27 x 10(3)-3.36 x 10(5) copies/50 ng (median 4.33 x 10(4)copies/50 ng) and 29.38%-600.53% (median 48.12%) respectively.
  • One case showed significant decrease of PML/RAR alpha fusion gene transcripts after induction therapy compared to that at the time of diagnosis, while the fusion transcripts significantly increased after relapsed.
  • CONCLUSION: RQ-PCR is a sensitive, reliable quantitative assay and can be used in the diagnosis of APL and measurement of MRD.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / genetics. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Reproducibility of Results. Young Adult

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18543226.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  •  go-up   go-down


96. Schwarz J, Korístek Z, Starý J, Zák P, Kozák T, Marková J, Michalová K, Dvoráková D, Mayer J, Cetkovský P: [Therapy of acute promyelocytic leukemia in Czechia: results and analysis of prognostic factors]. Vnitr Lek; 2008 Jul-Aug;54(7-8):757-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy of acute promyelocytic leukemia in Czechia: results and analysis of prognostic factors].
  • We have retrospectively evaluated a cohort of 144 patients (including 17 pediatric ones) with de novo acute promyelocytic leukemia registered in databases of institutions cooperating within the CELL group (The Czech Leukemia Study Group for Life).
  • This result was better than that of patients treated by chemotherapy only (n = 15; CR 46.7%; P = 0.003) or by ATRA monotherapy (n = 13; CR 62.5%; P = 0.17).
  • FAB M3v morphology, LDH serum level, fibrinogen level, presence of internal tandem duplication (ITD) of the FLT3 gene (which was strongly associated with leukocytosis and also with the short PML/RARalpha transcript resulting from the bcr3 break in the PML gene).
  • [MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18780575.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


97. Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA, Wharton SB, Jellinek DA, Arbuckle SM, Yoo J, Robinson BG, Learoyd DL, Stalley PD, Bonar SF, Yu D, Pollock RE, Reddel RR: A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res; 2005 Jan 1;11(1):217-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: To assay for ALT, we detected ALT-associated promyelocytic leukemia (PML) bodies (APBs) by combined PML immunofluorescence and telomere fluorescence in situ hybridization.
  • APBs are PML nuclear domains containing telomeric DNA and are a known hallmark of ALT in cell lines.
  • The APB assay concurred with the standard ALT assay in 62 of 62 tumors and showed that 35% of 101 soft tissue sarcomas (STS), 47% of 58 osteosarcomas (especially younger patients), 34% of 50 astrocytomas, and 0% of 17 papillary thyroid carcinomas were ALT positive (ALT+).
  • [MeSH-minor] Adult. Aged. Apoptosis. Blotting, Southern / methods. Cell Aging. Cell Line, Tumor. Cell Nucleus / metabolism. Child. Humans. Leukemia, Promyelocytic, Acute / diagnosis. Leukemia, Promyelocytic, Acute / metabolism. Middle Aged. Osteosarcoma / diagnosis. Osteosarcoma / metabolism. Telomerase / metabolism. Thyroid Neoplasms / metabolism. Time Factors

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671549.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


98. Qiu HR, Li JY, Zhu Y, Hong M, Wang R, Xu W: [A case of acute promyelocytic leukemia with double ider (17q-)]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec;15(6):1309-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of acute promyelocytic leukemia with double ider (17q-)].
  • This study reported a relapsed case of acute promyelocytic leukemia with complex chromosomal aberrations of double ider (17q-) and explored its laboratory and clinical features.
  • In conclusion, double ider (17q-) is a rare additional abnormality in APL patients; combination of FISH with M-FISH techniques is a reliable way to identify such complicated chromosomal aberrations.

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18088491.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


99. Xiang Y, Wang XB, Sun SJ, Guo AX, Wei AH, Cheng YB, Huang SL: [Compound huangdai tablet as induction therapy for 193 patients with acute promyelocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2009 Jul;30(7):440-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Compound huangdai tablet as induction therapy for 193 patients with acute promyelocytic leukemia].
  • OBJECTIVE: To report the results of curative and adverse effects of compound huangdai tablet (CHDT) as induction therapy for 193 patients with acute promyelocytic leukemia (APL).
  • There was no change in lanine transaminase, urea, creatinine or electrocardiographic QTc interval in 110 APL patients observed before and after the treatment.
  • CONCLUSION: CHDT therapy is a modality of higher CR rate, good safety and tolerance without bone marrow suppression for APL patients.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy. Phytotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Plant Preparations / adverse effects. Plant Preparations / therapeutic use. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954593.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Plant Preparations
  •  go-up   go-down


100. Tsimberidou AM, Tirado-Gomez M, Andreeff M, O'Brien S, Kantarjian H, Keating M, Lopez-Berestein G, Estey E: Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leuk Lymphoma; 2006 Jun;47(6):1062-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.
  • The present study aimed to investigate single-agent liposomal all-trans retinoic acid (Lipo-ATRA) in untreated acute promyelocytic leukemia (APL).
  • Idarubicin was added only if a polymerase chain reaction test for promyelocytic leukemia-retinoic acid receptor alpha (sensitivity level, 10(-4)), performed every 3 months from CR, was positive.
  • The observation that patients can be cured of APL without the use of chemotherapy should encourage further study of 'targeted' therapy in APL and in other leukemias.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / metabolism. Liposomes / therapeutic use. Tretinoin / therapeutic use
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / pharmacology. Disease-Free Survival. Female. Humans. Idarubicin / pharmacology. Male. Middle Aged. Receptors, Retinoic Acid / metabolism. Remission Induction. Texas

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840198.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 5688UTC01R / Tretinoin; ZRP63D75JW / Idarubicin
  •  go-up   go-down






Advertisement